Cash Burn Slows; Coverage Catalysts in Focus

21 May 2024

AUDITED FINANCIAL RESULTS FOR THE YEAR TO 31 MARCH 2024

CASH BURN SLOWS; COVERAGE CATALYSTS IN FOCUS

FINANCIAL AND PERFORMANCE HIGHLIGHTS
1

• Operating revenue increases 22% to $23.9 million; total revenue increases 12% to $29.3
million lifted by a 2% rise in commercial Cxbladder test volumes in the US market and
increased collections.
• Average US Sales Price (ASP)
2
per test increased 18% from US$519 in 2H 23 to US$613
in 2H 24 following improvements in cash collection and increased volumes from our major
private payer Kaiser Permanente.
• Total laboratory throughput
3
(TLT) of Cxbladder tests increases 3% to 32,633 tests,
commercial tests increased 2% to 27,347 with the rate of growth slowing in 2H 24 as the
sales team was reduced and further attrition of the team was not backfilled to preserve
capital.
• Cash burn reduced in 2H 24 to $11.9 million, down 24% on 1H 24 following reorganization;
use of capital tightly focused on long-term strategic imperatives. Net loss after tax increases
to $29.5 million from $27.0 million.
• End of period cash and cash equivalents of $50.3 million down from $62.2 million in
September 2023; a runway expected to be sufficient to support the company through to
regaining coverage in the event of a Medicare non-coverage determination.
STRATEGIC HIGHLIGHTS
• Refocused our operations on clinical development for Detect
+
and Monitor
+
for guidelines
inclusion and coverage certainty.
• STRATA
4
published in the Journal of Urology on May 3, 2024, 9 months ahead of prior
target; the study provides the strongest evidence yet for the inclusion of Cxbladder in
guidelines and featured prominently at the American Urological Association (AUA) annual
conference.
• Restructured our commercial operations on profitable territories and non-Medicare revenue
streams; sales messaging focused on clinical and economic value of Cxbladder.
• Achieved strong improvements in commercial team performance: sales force efficiency
(total tests/average FTE) rises 59% from Q4 23 to Q4 24; and the team is now operating
at breakeven.
• Awaiting a finalization of the draft ‘Genetic testing for oncology’ (DL39365) Medicare Local
Coverage Determination; Pacific Edge is prepared for all outcomes.

1
All comparisons are to the same period of the prior financial year unless otherwise stated.
2
ASP is US Operating Revenue in USD/US Commercial Test Volumes
3
Total Laboratory Throughput includes commercial, pre-commercial and clinical studies testing.
4
STRATA means the Safe Testing of Risk for Asymptomatic Microhematuria study undertaken by Pacific Edge

2

DUNEDIN, New Zealand – Pacific Edge (NZX, ASX: PEB) today reports successful execution
of strategic initiatives to focus the company on the development of its advanced cancer
diagnostic tests for inclusion in clinical guidelines and gaining coverage certainty from
Medicare and other healthcare payers.
Operating revenue increased 22% to $23.9 million from $19.6 million in FY 23, slowed by the
underlying reduction in commercial test volume in 2H 24. Total laboratory throughput (TLT)
growth slowed in the second half of the year. This followed the reduction of the sales team in
Q2 24 to drive efficiency and preserve capital as the company waits for the finalization of the
draft ‘Genetic testing for oncology’ (DL 39365) Medicare coverage determination. TLT
increased 3% to 32,633 tests from 31,565 in FY 23 while commercial test volumes increased
2% to 27,347 tests from 26,691 in FY 23.
Operating revenue was also supported by an 18% improvement in the US average sales price
(ASP; average US dollar revenue/commercial tests) from US$519 in 2H 23 to US$613 in 2H
24. This result followed from improvements in collection processes (see below), an increase in
volume of tests from our major US customer Kaiser Permanente and Medicare coverage of
Triage since January 2023. Total revenue, which includes interest income on cash reserves,
government grants and foreign exchange movements, increased 12% to $29.3 million from
$26.1 million in the same period a year ago. The net loss for the year of $29.5 million was wider
than the $27.0 million in the prior year as the company continued to invest in long-term growth
initiatives and incurred one-off restructuring costs.
Cash burn fell sharply in 2H 24 to $11.9 million, down 24% on 1H 24 following the
reorganization. Pacific Edge ended the period with cash, cash equivalents and short-term
deposits of $50.3 million down from $62.2 million in September 2023.
Chairman Chris Gallaher said: “The Board is pleased with the progress Peter and his team
have made as we work towards gaining certainty on Medicare coverage of our tests. They
have acted swiftly regarding the need to preserve capital through uncertainty and retained their
focus on the strategic imperatives in clinical evidence generation that will underpin our future
success and prepare the company for all outcomes.
“As announced in March, I will be stepping down as the Chairman of Pacific Edge at the end
of the year. The Board is working through the Nominations Committee to identify my successor
who will lead the Company into the next phase of its development.”
Chief Executive Dr Peter Meintjes said: “I remain confident in our ability to navigate the
challenges we’ve faced regarding coverage and the normal hurdles faced by fast-growing
companies. We are a more efficient organization and will continue to execute on the strategies
that justify confidence in our long-term prospects.”
STRATEGIC PROGRESS
Pacific Edge has refocused on the clinical development of our new Detect
+
and Monitor
+
tests
for guidelines inclusion and coverage certainty, no matter the outcome of the impending

3

Medicare local coverage determination. We are delighted to report that this strategy is already
delivering on its goals.
Our sales strategy prioritizes profitable sales territories, non-Medicare revenue streams and
cash preservation over top line revenue growth alone. We have aligned our sales messaging
to embed the clinical value of Cxbladder to the physician and patient, and its economic value
to health systems and payers.
The shift in focus has delivered improvements in the US commercial team’s performance: sales
force efficiency (total tests/average FTE) has risen 59% from 239 in Q4 23 to 381 in Q4 24.
The sales team is now operating at breakeven.
US clinical commitment to Cxbladder is steady at 6.7 tests per unique ordering clinician
although the number of ordering clinicians has fallen. This result reflects the reduced reach of
our team but demonstrates the improvement in clinical mix in favor of clinicians that understand
the clinical utility of our tests.
Improved US collection processes have delivered what we believe will be an enduring lift in
ASP from US$519 in 2H 23 to US$613 in 2H 24. These processes include initiatives to ensure
patients with non-contracted private payers take responsibility for test payments (a program
that will be rolled out to Medicare patients in the event of a non-coverage determination). The
ASP has also been supported by ongoing initiatives to digitalize Cxbladder information flows
that improve test ordering, resulting in improved payment collection.
More broadly we have diversified our revenue streams reaching out to new growth territories
in Asia, the Middle East, Latin America and Australia that over the longer term can be
developed to deliver meaningful demand for Cxbladder. In the last year this has seen the
appointment of six distributors of our tests.
We have continued to advance the commercialization of Detect
+
, the first of our tests to be
brought to market deploying performance enhancing DNA biomarkers. The test’s CPT
4
code
became effective at the start of this calendar year and our attention is now focused on Medicare
pricing of the test. This price will set a benchmark price for all other US healthcare payers.
If we are successful in our goal to have the test priced via the Centers for Medicare & Medicaid
Services (CMS) ‘Crosswalk’ process, we see the potential for a higher price and higher margin
than our existing tests, a result that would strengthen the underlying economics of the direct
sales team and the company.
Our clinical evidence generation program is operating within a structured framework for
Analytical Validity (AV), Clinical Validity (CV) and Clinical Utility (CU), the endpoints required
for coverage decisions and guideline inclusion.

4
A CPT (Current Procedural Terminology) code is a medical code used to describe medical, surgical, and diagnostic
services and procedures in the US healthcare system.

4

Our STRATA study achieved the significant milestone of publication in the Journal of Urology
in May, nine months ahead of schedule. The study headlined at the American Urological
Association (AUA) annual conference, the world’s largest urological meeting, and provides the
strongest evidence yet for the inclusion of Cxbladder in guidelines for hematuria evaluation.
Specifically, it demonstrated Cxbladder can safely and more effectively risk-stratify low risk
hematuria patients when compared to AUA guidelines, thereby reducing the number of
unnecessary invasive cystoscopies.
Over the next two years the publication of results from our DRIVE and microDRIVE studies are
expected to provide new CV evidence for Triage and Detect
+
, while a separate study will
demonstrate the Analytical Validity of all our current generation of tests under a new protocol
that automates the RNA extraction. All publications offer new opportunities for guideline
inclusion and, in the event of a non-coverage determination, an opportunity to seek
reconsideration of coverage.
Finally, the company’s research and development efforts have been orientated toward the
launch of Detect
+
and Monitor
+
. Simultaneously, we have focused on our Cxbladder
simplification projects that aim to reduce technician operator times, reduce sample turnaround
times and lower the cost of goods. These changes simplify the workflow for a potential kit-
based product distribution and decentralized deployment as an IVD in international markets.
GOVERNANCE
Pacific Edge has continued to evolve its governance framework. A key focus is now on the
succession plans for Mr Gallaher and Independent Director Mark Green, who both notified
Pacific Edge of their intention to retire later this year. The Board’s Nomination Committee has
begun a process to recruit new Directors.
Meanwhile, in our Annual Report to be published in late June we will release our first Climate
Related Disclosure report in compliance with the new Aotearoa New Zealand Climate
Standards. We will also detail the changes we have made to deliver on the environmental,
social and governance expectations of our stakeholders.
OUTLOOK
Dr Meintjes said the finalization of the Medicare coverage determination remains the biggest
determinant of the company’s prospects for the immediate future, with a decision due by 26
July 2024
5
.
“A non-coverage determination is likely to impact US volumes, but we are well prepared with
plans to regain coverage and, should coverage be affirmed, rebuild the momentum in the
clinical adoption of Cxbladder in the US and around the world.
“In the event of a non-coverage determination, these strategies include a potential legal
challenge to the determination; Medicare patients assuming responsibility for the payment of

5
US time (27 July New Zealand time)

5

Cxbladder tests; and the continued advancement of our clinical evidence program, which will
give us multiple opportunities to seek a Medicare coverage reconsideration,” Dr Meintjes said.
“Meanwhile, we see several catalysts to the company accelerating the adoption of Cxbladder
and driving improvements in shareholder value. In addition to a positive Medicare
determination, these include the favorable pricing of Detect
+
and then the launch of the test,
targeted for early 2025. The publication of new clinical evidence, meanwhile, offers new
opportunities for the inclusion of our tests in clinical guidelines.
“We remain confident of our prospects in both the short and long-term and look forward to
updating you on our progress in the coming months,” Dr Meintjes said.
CONFERENCE CALL
Pacific Edge is holding an investor briefing at 11.00am (NZT) today. It is available through the
following like: www.virtualmeeting.co.nz/pebfy24 or by phone on the following toll-free
numbers:
• New Zealand: 0800 005 652
• Australia: 1800 953 093
• USA & Canada: 888 672-2415
Conference ID: 7745991

Released for and on behalf of Pacific Edge by Grant Gibson, Chief Financial Officer.
For more information:
Investors: Media:
Dr Peter Meintjes Richard Inder
Pacific Edge, Chief Executive The Project
P: +64 22 032 1263 P: +64 21 645 643
OVERVIEW
Pacific Edge: www.pacificedgedx.com
Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way
in the development and commercialization of bladder cancer diagnostic and prognostic tests
for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in
Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its
wholly owned, and CLIA certified, laboratories in New Zealand and the USA.
Cxbladder: www.cxbladder.com
Cxbladder is a urine-based genomic biomarker test optimized for the detection and surveillance
of bladder cancer. The Cxbladder evidence portfolio developed over the past 14 years includes
more than twenty peer reviewed publications for primary detection, surveillance, adjudication

6

of atypical urine cytology and equivocal cystoscopy. Cxbladder is the focal point of numerous
ongoing and planned clinical studies to generate an ever-increasing body of clinical utility
evidence supporting adoption and use in the clinic to improve patient health outcomes.
Cxbladder has been trusted by over 4,400 US urologists in the diagnosis and management of
more than 100,000 patients, including the option for in-home sample collection. In New
Zealand, Cxbladder is accessible to 75% of the population via public healthcare and all
residents have the option of buying the test online.

---

Pacific Edge’s ordinary shares trade on the
NZX and the ASX under the ticker code: PEB
Pacific Edge
FY 24 FINANCIAL RESULTS

INVESTOR PRESENTATION
Dr Peter Meintjes
Chief Executive Officer
Grant Gibson
Chief Financial Officer
21 May 2024

IMPORTANT NOTICE AND DISCLAIMER
This presentation has been prepared by Pacific Edge Limited (PEL) solely
to provide interested parties with further information about PEL and its
activities at the date of this presentation.
Information of a general nature
The information in this presentation is of a general nature and does not
purport to be complete nor does it contain all the information which a
prospective investor may require in evaluating a possible investment in
PEL or that would be required in a product disclosure statement,
prospectus or other disclosure document for the purposes of the New
Zealand Financial Markets Conduct Act 2013 (FMCA) or the Australian
Corporations Act 2001. PEL is subject to a disclosure obligation that
requires it to notify certain material information to NZX Limited (NZX)
and ASX Limited (ASX) for the purpose of that information being made
available to participants in the market and that information can be found
by visiting www.nzx.com/companies/PEB and
www2.asx.com.au/markets/company/PEB. This presentation should be
read in conjunction with PEL’s other periodic and continuous disclosure
announcements released to NZX and ASX.
Not an offer
This presentation is for information purposes only and is not an
invitation or offer of securities for subscription, purchase or sale in any
jurisdiction where such offer purchase or sale would not be permitted.
Not financial product advice
This presentation does not constitute legal, financial, tax, financial
product advice or investment advice or a recommendation to acquire
PEL securities and has been prepared without taking into account the
objectives, financial situation or needs of investors. Before making an
investment decision, prospective investors should consider the
appropriateness of the information having regard to their own
objectives, financial situation and needs and consult an NZX Firm,
solicitor, accountant or other professional advisor if necessary.
Forward-looking statements
This presentation may contain forward-looking statements that reflect
PEL’s current views with respect to future events. Forward-looking
statements, by their very nature, involve inherent risks and
uncertainties. Many of those risks and uncertainties are matters which
are beyond PEL’s control and could cause actual results to differ from
those predicted. Variations could either be materially positive or
materially negative. The information is stated only as at the date of this
presentation. Except as required by law or regulation (including the NZX
Listing Rules and ASX Listing Rules), PEL undertakes no obligation to
update or revise any forward-looking statements, whether as a result of
new information, future events or otherwise. To the maximum extent
permitted by law, the directors of PEL, PEL and any of its related bodies
corporate and affiliates, and their respective officers, partners,
employees, agents, associates and advisers do not make any
representation or warranty, express or implied, as to the accuracy,
reliability or completeness of such information, or the likelihood of
fulfilment of any forward-looking statement or any event or results
expressed or implied in any forward-looking statement, and disclaim all
responsibility and liability for these forward-looking statements
(including, without limitation, liability for negligence).
Financial data
All dollar values are in New Zealand dollars unless otherwise stated. This
presentation should be read in conjunction with, and subject to, the
explanations and views of future outlook on market conditions, earnings
and activities given recent announcements to the NZX and ASX.
Effect of rounding
A number of figures, amounts, percentages, estimates, calculations of
value and fractions in this presentation are subject to the effect of
rounding. Accordingly, the actual calculation of these figures may differ
from the figures set out in this presentation.
Past performance
Investors should note that past performance, including past share price
performance, cannot be relied upon as an indicator of (and provides no
guidance as to) future PEL performance, including future financial
position or share price performance.
Investment risk
An investment in securities of PEL is subject to investment risk and other
known and unknown risks, some of which are beyond the control of PEL.
PEL does not guarantee any particular return or the performance of PEL.
Disclaimer
None of PEL or PEL’s advisers or any of their respective affiliates, related
bodies corporate, directors, officers, partners, employees and agents,
have authorised, permitted or caused the issue, submission, dispatch or
provision of this presentation and, except to the extent referred to in
this presentation, none of them makes or purports to make any
statement in this presentation and there is no statement in this
presentation which is based on any statement by any of them.
To the maximum extent permitted by law, none of PEL and its advisers,
affiliates, related bodies corporate, nor their respective directors,
officers, partners, employees and agents makes any representation or
warranty, express or implied, as to the currency, accuracy, reliability or
completeness of information in this presentation; and none of them shall
have any liability (including for negligence) for:
•any errors or omissions in this presentation; or
•any failure to correct or update this presentation, or any other
written or oral communications provided in relation to this
presentation; or
•any claim, loss or damage (whether foreseeable or not) arising from
the use of any information in this presentation or otherwise arising in
connection with this presentation or the information contained in it.
By receiving this presentation, you agree to the above terms and
conditions.
2

1.FY 24 HIGHLIGHTS
2.STRATEGIC DELIVERY
3.FINANCIAL PERFORMANCE
4.ESG & OUTLOOK
5.QUESTIONS
AGENDA

FY 24 HIGHLIGHTS: PREPARED FOR ALL OUTCOMES AS WE REDUCE CASH BURN
24%
DROP IN MONTHLY
CASH BURN
3
IN 2H
24 VS 1H 24
Global TLT of 32,633; global
commercial volumes rise 2%
to 27,347
Increase from ($27.0M) on
FY 23 lifted by increased
investment in clinical
evidence
$50.3M
CASH, CASH
EQUIVALENTS
3
Balance sheet is expected to
provide sufficient runway to
regain Medicare coverage
(if withdrawn)
22%
GROWTH IN
OPERATING
REVENUE on
FY 23
3%
1
GLOBAL TESTING
VOLUMES
(TLT
2
) on FY 23
($29.5M)
NET LOSS AFTER
TAX
Operating revenue $23.9M
Total revenue of $29.3M up
12% on FY 23.FX gains of
$0.6m vs $2.3m FY23
1.All comparisons are to the same period in the prior year unless otherwise stated
2.TLT is the Total Laboratory Throughput including commercial, pre-commercial and clinical studies testing
3.Cash, cash equivalents and short-term deposits
4
Cash and Cash Equivalents
decreased $11.9M in 2H 24
vs $15.6M in 1H 24 after
reorganization in Q2 24
•Refocused the business on clinical development for Detect
+
and Monitor
+
•Published Clinical Utility for Triage from STRATA in The Journal of Urology and presented in paradigm shifting session at AUA 2024
•Restructured our commercial operations on profitable territories and non-Medicare revenue streams
•Reduced average monthly cash burn by 24% from $2,603k in 1H 24 to $1,985k in 2H 24
•Improved US cash collections by 18% with average sales price (ASP) increasing from US$519 2H 23 to US$613 in 2H 24
•Adjusted sales messaging to the clinical and economic value of Cxbladder
•Well prepared for all outcomes; awaiting decision on Medicare coverage

VALUE CREATION THROUGH THREE PILLARS
OUR PEOPLE
OUR PROCESSES
OUR IP, KNOWLEDGE
AND EXPERIENCE
OUR CLINICAL STUDIES
PARTNER SITES
OUR INVESTORS
EARLY DETECTION AND
CLINICALLY ACTIONABLE CARE
INNOVATION PIPELINE FOR
CLINICAL APPLICATIONS
INCLUSIVE WORKPLACE
DRIVEN BY OUTCOMES
INCREASED LONG-TERM
SHAREHOLDER VALUE
EXCELLENT PATIENT EXPERIENCE
AND ACCURATE RESULTS
INPUTSOUTPUTS
A VALUES-DRIVEN, DIVERSE, RESULTS-FOCUSED CULTURE
SCALABLE PROCESSES, AUTOMATED OPERATIONS, CONTINUOUS IMPROVEMENT
DIGITALIZED ARCHITECTURE, SEAMLESS VIRTUAL COLLABORATION, REAL-TIME ANALYSIS
EVIDENCE,
COVERAGE AND
GUIDELINES
RESEARCH
AND
INNOVATION
ADOPTION,
RETENTION AND
REVENUE
GENERATION

17%
61%
22%
21%
57%
22%
GROWTH SLOWED AMID MEDICARE DRAFT
FY 23
TEST VOLUMES BY TYPE (TLT*)
GLOBAL COMMERCIAL TEST VOLUMES (TLT*)
GLOBAL TOTAL TEST VOLUMES (TLT*)
FY 24 TOTAL LAB THROUGHPUT (TLT*)
•Global TLT increased 3% to 32,633 with test demand moderating
amid proposed Medicare coverage changes & sales force reductions.
•Global Commercial test volumes increased 2%. Global TLT is driven
by US growth in the US (predominantly Detect).
•Risk stratification during hematuria evaluation using Triage & Detect
is the largest market opportunity & reflected in current volume mix.
*TLT is the Total Laboratory Throughput including commercial, pre-commercial and clinical studies testing
FY 24
6
1H
2H
1H
2H
8,147
6,864
11,136
14,920
18,240
8,714
8,950
11,950
16,645
14,393
16,861
15,814
23,086
31,565
32,633
-
5,000
10,000
15,000
20,000
25,000
30,000
35,000
FY 20FY 21FY 22FY 23FY 24
TESTS
6,573
5,591
9,192
12,422
15,401
7,054
7,385
10,004
14,269
11,946
13,627
12,976
19,196
26,691
27,347
-
5,000
10,000
15,000
20,000
25,000
30,000
FY 20FY 21FY 22FY 23FY 24
TESTS

7
CAPITAL PRESERVATION AND NEW REVENUE SOURCES DELIVERS RESILIENCE
COMMITTED TO MAINTAINING A STRONG BALANCE SHEET
•Pacific Edge continues to manage its cash reserves so - in the event
of an adverse Medicare coverage decision - we have a cash runway
to regain coverage.
•Cash reserves of $50.3m; cash burn of$11.9m in 2H 24 vs$15.6m
in 1H24.
STRATEGIC RESPONSE TO MEDICARE DELIVERING GAINS
•Restructured US sales operations and introduced patient
responsibility.
•Deeper focus on larger or value-based institutional accounts and
capitated systems (pop: ~13.2m patients).
•Refocused clinical evidence development, coverage and guidelines
for coverage certainty.
•Ex-US opportunities through distributors: ProGenetics (Israel) and
SouthGenetics (multiple LATAM countries).
•Considering alternative Medicare Administrative Contractor, LCD
Challenge & new LCDs.
EXTENDING OUR REACH THROUGH DISTRIBUTION AGREEMENTS
APAC & HEAD OFFICE STRATEGY SHIFT COMPLETE
•Cash burn is now driven almost entirely by long-term strategic
imperatives.
•Development of growth markets in Australia and Asia.
•Distribution agreements Transviet (Vietnam), Hi-Precision (Philippines)
and WellSpring (Malaysia) and Emmed (Brunei) delivering small but
increasing volumes.

8
FOUNDATIONS FOR GROWTH - US TEST VOLUMES STABILISE
•Throughput has reduced by 22% from 7,816 test/quarter in Q4
23 to 6,099 in Q4 24 as the average sales team for the quarter
has reduced by 51%.
•Most-recent QoQ throughput volume is steady (6,099 in Q4 24
over 6,041 in Q3 24) despite further reduction in sales FTEs.
•Sales territories are larger and more challenging for sales reps,
but focus has been on larger, more reliable accounts.
•Messaging has focused on communicating the clinical value of
Cxbladder for risk stratification to reduce cystoscopies and the
associated economics of adopting on all appropriate patients.
US TOTAL TEST VOLUME*
*
Total Laboratory Throughput in the US including commercial, pre-commercial and clinical studies testing
SMALLER SALES TEAM REDUCES TOP LINE THROUGHPUT
4,277
4,706
4,591
5,290
6,073
6,699
6,629
7,816
8,627
7,335
6,041
6,099
-
1,000
2,000
3,000
4,000
5,000
6,000
7,000
8,000
9,000
Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24
TEST VOLUMES

9
FOUNDATIONS FOR GROWTH – SALES TEAM PERFORMANCE IMPROVES
US SALES FORCE EFFICIENCY
21.3
23.3
28.7
28.3
27.3
29.7
33.0
32.7
30.0
27.7
20.7
16.0
200
202
160
187
222
226
201
239
288
265
292
381
0
50
100
150
200
250
300
350
400
-
10.0
20.0
30.0
40.0
50.0
60.0
Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24
TESTS* /SALES FTE
AVERAGE SALES FTE
US TEST VOLUME/SALES FTE (RHS)
657
690
741
789
895
978
1,082
1,150
1,232
1,147
1,016
915
6.5
6.8
6.2
6.7
6.8
6.8
6.1
6.8
7.0
6.4
5.9
6.7
-
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
-
200
400
600
800
1,000
1,200
1,400
1,600
Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24
TEST*/ORDERING CLINICIAN
US ORDERING CLINICIANS
TESTS/ORDERING CLINICIAN (RHS)
US CLINICAL COMMITMENT
•Sales FTE down to an average of 16.0 in Q4 24 from 32.7 in Q4
23 as we focused on cash conservation.
•Sales FTEs were reduced by restructure in late Q2 24.
•Sales FTEs have continued to leave the business and not
currently backfilled due to focus on cash preservation.
•Sales force efficiency (total tests/average FTE) up 59% from Q4
23 to 381:
•More effective core sales team.
•Focus on the most profitable territories/accounts.
•Tests/US ordering clinician stable, but ordering clinicians fall
reflecting:
•Change in clinical mix in favor of clinicians that
understand the clinical utility of Cxbladder.
•Reduced reach of the direct sales team.
•Direct sales team have achieved operational break even.
SALES TEAM FOCUSED ON KEY PERFORMANCE INDICATORS

10
FOUNDATIONS FOR GROWTH - US CASH COLLECTIONS IMPROVE
•Average Sales Price (ASP) per test increased 18% to US$613 in
2H 24 from US$519 in 2H 23 lifted by:
•Enhanced Patient Responsibility - patients with non-
contracted private insurance (i.e. non-Kaiser) sign
patient responsibility notice agreeing to pay if their
insurer does not.
•Increased utilization of appropriate patient types from
Kaiser Permanente after EMR integration.
•Medicare reimbursement of Triage since Jan 2023.
•Improved medical necessity documentation to improve
billing and appeals processes for Medicare Advantage.
•Improved cash collections are typically permanent
improvements that we expect to maintain as we scale.
*
ASP: US Operating Revenue in USD / US Commercial Test Volumes
US COMMERCIAL TEST VOLUMES AND ASP* (US$)
REIMBURSEMENT & CASH COLLECTIONS – A CORE COMPETENCY
7,476
8,276
10,622
12,450
13,550
9,956
$472
$470
$493
$519
$562
$613
$-
$100
$200
$300
$400
$500
$600
$700
-
2,000
4,000
6,000
8,000
10,000
12,000
14,000
16,000
1H 222H 221H 232H 231H 242H 24
AVERAGE US SALES PRICE (US$)
TEEST VOLUME
US AVERAGE SALES PRICE (RHS)

11
For healthcare payers Cxbladder Detect offers substantial total cost savings per patientwhen used to
intensify or de-intensify hematuria evaluation in patients presenting with microhematuria
1
1
Pacific Edge has developed a detailed budget impact model to understand costs to private practice, healthcare institutions and payers, over and
above the Cxbladder test price of US $760/test focused on microhematuria patients. Budgetary Impact of Including the Urinary Genomic Marker
Cxbladder Detect in the Evaluation of Microhematuria Patients - PubMed (PMID: 37914255)
SELLING CXBLADDER’S CLINICAL, ECONOMIC AND PATIENT VALUE
Pacific Edge
modelling
1

suggests avoided
procedures could
save >US$500 per
patient with
microhematuria
CURRENT PRACTICE (AUA GUIDELINES)CXBLADDER INTRODUCED TO STANDARD OF CARE

DRIVING GROWTH IN ASIA PACIFIC AND CONSOLIDATING NEW ZEALAND
APAC TOTAL TEST VOLUMES
*
*
Total Laboratory Throughput in Asia and Pacific including commercial, pre-commercial and clinical studies testing
COMMERCIAL TEST VOLUME GROWTH IN NEW MARKETS
•Quarterly total test volumes steady across FY 24.
•Fewer evaluations and non-billable tests.
•Shift in emphasis to commercial tests.
•2H 24 commercial test volumes rose 9% over 2H 23
•New Zealand is a mature market with Cxbladder utilized in 15 of the
20 Te Whatu Ora health regions covering >75% of the population.
AUSTRALIA & ASIA PACIFIC
•Australia and Southeast Asia are still in business development.
•Initial commercial testing volume direct or via distributors in
Singapore, Malaysia, and the Philippines.
12
1,716
1,728
1,800
1,819
1,851
1,989
-
200
400
600
800
1,000
1,200
1,400
1,600
1,800
2,000
1H 222H 221H 232H 231H 242H 24
TEEST VOLUME
APAC COMMERCIAL TEST VOLUMES
1,079
1,074
1,117
952
983
1,165
1,139
1,061
1,079
1,199
1,142
1,111
-
200
400
600
800
1,000
1,200
1,400
Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24
TEST VOLUMES

13
STRENGTHENING OUR FOUNDATIONS
DIGITALIZATION, AUTOMATION & CUSTOMER EXPERIENCE
Customer facing systems
•Give customers options to connect with Pacific Edge to
fit their needs and smooth workflows.
•Electronic Medical Record (EMR) integrations.
•Customer Portal.
•Improvement of end-to-end experience for patients and
customers supported by digital workflows.
Internal systems
•Improve Lab Operations and Customer Service with
focus on increasing automation and reducing turn
around time.
•Organization-wide data warehouse for storage, access
and reporting of all commercial data.
•Customer Relationship Management (CRM) rollout
expanded beyond sales to all commercial teams.
•EMR integration went live in Nov 2023 across the Southern California
Permanente Medical Group (Kaiser SoCal) streamlining sample collection,
test ordering and test resulting for Triage and Monitor.
•All 15 Kaiser SoCal sites are now ordering and volumes increasing steadily.
•Primarily adopted for Triage, Monitor volume is beginning to rise as
clinicians become increasingly familiar with Cxbladder.
•Ordering by nurses and clinical assistants suggests accounts are following
the protocols on all eligible patients for Triage and Monitor.
•Kaiser SoCal represents ~37% of the >12.6m members covered Kaiser
Permanente means plenty of growth opportunity remains within SoCal.
•NorCal and other regions remain a longer-term priority following success
in SoCal.
EMR INTEGRATION DRIVES MOMENTUM AT KAISER

1. RDM: Residual Disease Monitoring,
2. TRM: Therapeutic Response Monitoring
3. Lotan et al (2022) ‘Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification’
14
OUR
FUTURE
SIMPLIFYING THE CXBLADDER VALUE PROPOSITION – DETECT
+
& MONITOR
+
ADDITION OF DNA BIOMARKERS ENHANCES TEST PERFORMANCE
3

15
DETECT
+
PRICING VIA CROSSWALK COULD BOLSTER PACIFIC EDGE’S ECONOMICS
•Pricing of Detect
+
is the next step in establishing
reimbursement.
•Crosswalk strategy for Detect
+
is based on technological
similarities to previously priced tests:
•Existing CMS price for Cxbladder is the best
reference for RNA components of Detect
+
.

•Considering alternatives for the DNA components
based on multiplex ddPCR tests.
•Pacific Edge is seeking a higher price and higher gross
margin, further enhancing the economics of our sales
teams.
•Potential to set a precedent for Monitor
+
.
DETECT
+
PRICING – A POTENTIAL STEP CHANGE
Anticipated timeframe for Detect
+
pricing - dates may change

16
AWAITING ‘GENETIC TESTING FOR ONCOLOGY’ (DL 39365) RESPONSE
KEY OPINION LEADERS UNITED IN OPPOSITION TO DL39365
•Pacific Edge engaged with oncology diagnostics industry & urology community
during the ‘Review and Comment’ period.
•We have undertaken further meetings with Novitas and the Coverage and Analysis
Group at CMS (Centers for Medicare and Medicaid Services).
•We have enjoyed strong support from professional societies, diagnostics industry
partners, individual clinicians and patient advocacy groups for our arguments that
we retain coverage.
27 July 2023
Novitas
1
republishes draft LCD
9 September 2023
Review and commentperiod closes
29 November 2023
Pacific Edge meets with CMS in person
10 January 2024
Pacific Edge meets with Novitas and CMS
virtually
DECISION PENDING
Novitas must withdraw or finalize the LCD by 26 July
2024
2
. The LCD becomes effective (assuming no
further protest) a minimum of 45 days after
finalization
MEDICARE IS PACIFIC EDGE’S LARGEST PAYER
•Medicare and Medicare Advantage is the largest global opportunity in
bladder cancer diagnostics from a single coverage decision.
•In FY 24 Medicare and Medicare Advantage delivered ~14,000commercial
tests (~60% of US commercial tests) and ~$17.0m NZD in total operating
revenue (~71% of total operating revenue).
1 Novitas is the Medicare Administrative Contractor for Pacific Edge’s US laboratory. It is empowered by the Centers for Medicare and Medicaid Services (CMS) to
make the coverage determination, but it is accountable to CMS for the decision.
2 US time

17
STRATEGIC RESPONSES TO THE IMPENDING MEDICARE DETERMINATION
OUR RESPONSE TO AN AFFIRMATION OF COVERAGE
•Strategic review to accelerate the US adoption of
Cxbladder among patients, clinicians, and healthcare
payers.
OUR RESPONSE TO A LOSS OF COVERAGE
•Explore legal options supported by customers, industry
partners and other impacted companies.
•Immediately extend our ‘enhanced patient responsibility’
from commercially insured patients to include patients
covered by Medicare.
•Further review the structure of our operations and our
strategy to reduce cash burn in line with our plan to
regain Medicare coverage within our existing cash
reserves.
•Continue to explore other strategic alternatives for Pacific
Edge that could support the company through to
regaining Medicare coverage and advancing the
commercialization of Cxbladder globally.
LONG TERM VALUE CREATION STRATEGIES WILL CONTINUE
•Continue to advance our clinical evidence generation program for
inclusion in AUA and the National Comprehensive Cancer Network
(NCCN) Guidelines for increased coverage certainty.
•Continue to invest in medical affairs and the digitalization initiatives
that will enable clinicians who continue to order Cxbladder to
follow clinical pathways on all appropriate patient types.
Distribution of Current
U.S. Customers
Pacific Edge Diagnostics
USA, Hershey,
Pennsylvania

CLINICAL EVIDENCE UNDERPINS COVERAGE AND GUIDELINES DECISIONS
Recognition in national guidelines is the best way to entrench Medicare coverage of Cxbladder and its
adoption by other independently contracted healthcare systems
•Leading urologic authority in Europe and
globally influential.
•Relevant standards of care: non-muscle
invasive bladder cancer.
•Review period: with new evidence, last
updated in March 2024.
•US-based not-for-profit alliance of 32
leading US cancer centres. Novitas cited
NCCN as sufficient for coverage in draft LCD.
•Relevant standards of care: High-risk non-
muscle-invasive bladder cancer.
•Review period: annual submission every
August.
www.auanet.orgwww.nccn.orgwww.uroweb.org
•Globally the most influential and largest
urologicalassociation.
•Relevant standards of care: Hematuria,
microhematuria management and non-
muscle invasive bladder cancer (NMIBC).
•Review period: with new evidence, last
updated in 2020.
RECENT GUIDELINE MOVEMENTS
•The AUA amended the NMIBC guidelines in Jan 2024 after reviewing the literature on urine biomarkers for surveillance of NMIBC. Cxbladder
Monitor was not mentioned in the amendment, but explicitly named in “Future Directions” as a promising technology.
1
•The EAU updated their guidelines to say that biomarkers may have value in initial evaluation of hematuria, citing Cxbladder and three other
technologies based on their publications.
2
1 https://www.auanet.org/guidelines-and-quality/guidelines/bladder-cancer-non-muscle-invasive-guideline
2 https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer

STRATA
1
– THE STRONGEST EVIDENCE YET FOR GUIDELINE INCLUSION
PARADIGM-SHIFTING STUDY DEMONSTRATES CLINICAL UTILITY OF TRIAGE
•STRATA is the first ever randomized controlled trial of a urine biomarker for
hematuria evaluation:
•Peer reviewed study published in the AUA Journal of Urology
2
showed
clinicians undertook 59% fewer cystoscopies, when provided a
Cxbladder Triage test result.
•Seeking to leverage data to demonstrate the clinical utility of Detect
+
.
•Publication submitted to Novitas as it considers finalization of draft LCD.
•New evidence for inclusion in the Pacific Edge Clinical Dossier that we use to
engage with guideline committees, private payors, government payers,
value-based clinician groups ex-US distributors.
•STRATA data to be deployed to further improve the Detect
+
algorithm.
19
“Cxbladder Triage can help reduce the burden of unnecessary
cystoscopies in this population resulting in less patient
morbidity and discomfort, improved access to care, and
reduced environmental impact.” – Lotan et al. (2024)
1.Safe Testing of Risk for AsymptomaTic microhematuriA
2.Lotan et al (2024) https://doi.org/10.1097/JU.0000000000003991
USING CLINICAL EVIDENCE TO DRIVE CXBLADDER ADOPTION
STRATA lead author Yair Lotan presenting the study to the 2024
AUA annual meeting, following publication of the study in
Journal of Urology.

20
INCREASING CXBLADDER BRAND AWARENESS AT THE AUA CONFERENCE
•AUA annual meeting is the largest and most influential event in the US and global urological calendar. Provides opportunity
to engage over 10,000 urologists, urologic oncologists, advanced practice providers, and other healthcare professionals.
•2024 presence in San Antonio reinforced positioning and delivered core messaging, while promoting STRATA publication - both
before and after Dr Lotan’s podium presentation. Activities included:
•Prominent booth in main hall, staffed by the Pacific Edge Commercial Team for lead gathering and key account management
•Elevator takeovers to engage clinicians as they waited at leading event venues – Marriott and Grant Hyatt
•Targeted booth presence at the Urological Society for American Veterans (USAV) sub-meeting
•Agenda-driven micro-meetings for medical affairs, clinical studies, business development and key account management
Free standing pull-ups helped to promote STRATA
Mounted screens focused on core clinical
pathways – hematuria and surveillance

CLINICAL EVIDENCE CATALYSTS FOR COVERAGE CERTAINTY
21
MEDICARE RECONSIDERATION AND GUIDELINE INCLUSION REQUESTS
(Reconsideration requests take Novitas
1
approximately 12 months to process from the lodging of a valid request)
CatalystTest and evidence standard
(2)
Expected date of reconsideration request
(3)
1. STRATA data published-CU of TriageNovitas notified of the publication in April
2. Analytical Validation of automated
RNA and DNA extraction published
-AV of Triage, Detect, Detect
+
, Monitor and
Monitor
+
Q3 2024
3. DRIVE data published-CV of Detect
+
-CV of Triage
Q2 2025
4. Kaiser Permanente RWE
4
published-CU (RWE) of TriageQ2 2025
5
5. microDRIVE published-CV of Detect
+
Q3 2025
6. AUSSIE data published-CVof Detect
+
Q4 2025
7. Pooled CV data published
6
-CV of Detect
+
Q1 2026
8. LOBSTER published-CV of Monitor/Monitor+Q1 2026
9. CREDIBLE data published-CU of Detect
+
Q1 2028
1
Novitas is the Medicare Administrative Contractor (MAC) charged with making the Medicare local coverage determination for Pacific Edge’s US laboratory
2
AV, CV CU, respectively Analytical Validity, Clinical Validity, Clinical Utility
3
All dates are calendar year rather than financial year and our best current estimates
4
RWE is Real World Evidence
5
Timeline determined by Kaiser Permanente
6
The pooled analysis brings together data from DRIVE, AUSSIE and microDRIVE
Pacific Edge will also lodge a reconsideration request if Cxbladder is included in the American
Urological Association (AUA) or National Comprehensive Cancer Network (NCCN) guidelines

22
FDA PUBLISHES FINAL RULE TO REGULATE LAB DEVELOPED TESTS
US FDA REGULATION PUBLISHED. FACES HURDLES
•The FDA
1
published a final rule on 29 April 2024 asserting that it has the right to regulate
LDTslike Cxbladder as Medical Devices under the Medical Device Amendments of 1976.
•Enforcement discretion for pre-market approval (PMA) has been proposed for currently
marketed tests that are NYS accredited, meaning that existing Cxbladder tests will receive
enforcement discretion.
•New Cxbladder tests may be required to follow the steps of the ‘Phase Out’ of
enforcement discretion, but currently pose no risk to Detect
+
launch plans
•Pacific Edge’s position
•Pacific Edge supports and welcomes FDA regulation through an Act of Congress,
e.g. VALID
2
Act (failed to pass Congress in 2022).
•Pacific Edge does not support regulation under the Medical Device Amendments of
1976.
•Pacific Edge is prepared and already adapting
•While some requirements will be specific to the FDA, most are captured by other
regulatory bodies (CLIA, CAP & NYS
3
) with which we already comply.
•Pacific Edge continues to believe that the FDA will face legal and resourcing
challenges and that timelines are likely to be adjusted.
•Pacific Edge actively resources its R&D, clinical development, digital development
and clinical operations to maintain compliance with all regulatory requirements.
1.FDA: Food and Drug Administration
2.VALID: Verifying Accurate Leading-edge IVCT Development Act
3.CLIA: Clinical Laboratory Improvement Amendments, CAP:
College of American Pathologists, NYS: New York State

RESEARCH & INNOVATION – FOCUSED ON DNA ENHANCED PRODUCTS
READYING FOR THE LAUNCH OF NEW DETECT
+
AND MONITOR
+
•Ensure R&D, Digital and Lab Operations focus on the launch of Detect
+

and Monitor
+
•Simplifying Cxbladder:
•Aim to reduce technician time, lower cost of goods, lower
turnaround time, increase throughput and increase automation.
•Aim to be IVD-ready with “kittable” Cxbladder tests for
decentralized deployment for international market expansion.
•Analytical Validation (AV) of automated end-to-end lab
operations for RNA and DNA workflows.
•Publish AV Data on automated Cxbladder (Triage, Detect and
Monitor) targeting publication in Q3 2024*.
•Establish in-vitro diagnostic (IVD) regulatory framework for R&D of our
next generation tests.
•Continued engagement with industry and academic research and
development collaborations to address unmet clinical needs in bladder
cancer diagnosis and management.
23
*Calendar quarter

FY 24 FINANCIAL PERFORMANCE

$2,285
$3,326
$5,378
$8,707
$13,095
$2,085
$4,375
$6,067
$10,909
$10,812
$4,370
$7,701
$11,445
$19,616
$23,907
$0
$5,000
$10,000
$15,000
$20,000
$25,000
FY 20FY 21FY 22FY 23FY 24
$(000)
1H2H
▲
22%
5%
95%
4%
96%
25
US COMMERCIAL TEST VOLUME GROWTH DRIVING REVENUE
RATE OF REVENUE GROWTH IN 2H 24 SLOWS AMID SALE FORCE REORGANIZATION
PACIFIC EDGE OPERATING REVENUE
FY 23
FY 24
REGIONAL REVENUE CONTRIBUTION
APAC
AMERICAS

26
A RUNWAY SUFFICIENT TO WEATHER A NON-COVERAGE DETERMINATION
CASH BURN SLOWS AS CAPITAL PRESERVATION PROGRAM DELIVERS
•Cash, cash equivalents and short term
deposits of $50.3m as at 31 March 2024.
•Cash burn drops 24% on 1H 24 to $11.9m
ascapital preservation and sales efficiency
program delivers.
•Investment now primarily focused on long-
term strategic initiatives.
•Cash runway is expected to be sufficient to
regain coverage in the event of a non-
coverage determination.
A STRONG BALANCE SHEET
$105,412
$93,455
$77,791
$62,174
$50,261
$11,957
$15,664 $15,617
$11,913
$-
$2,000
$4,000
$6,000
$8,000
$10,000
$12,000
$14,000
$16,000
$-
$20,000
$40,000
$60,000
$80,000
$100,000
$120,000
31-Mar-2230-Sep-2231-Mar-2330-Sep-2331-Mar-24
CASH BURN ($000)
CASH AND CASH EQUIVALENTS ($000)
Half year cash and cash equivalent burn

27
REVENUE GROWS WITH INCREASED ADOPTION OF CXBLADDER
GROWTH MODERATES IN 2H 24 WITH REORGANIZATION CRIMPING SALES
•Operating revenue increased 22% in FY 24 vs FY
23with increased volumes and an increase in
average receipts.
•Operating revenuein 2H 24 drops vs 1H 24 due to
the restructuring to focus on profitable territories.
•Total revenue includes FX gains of $0.6m inFY 24,
lower than the$2.3m in FY 23.
•Operating expenses are up 11% FY 24 vs FY 23,
however are down 15% in 2H 24 vs 1H24 due to the
impactof therestructuringlate Q2 24.
•Balance sheet remains strong and expected to be
sufficient to regain coverage in the event of a non-
coverage decision.
FINANCIAL PERIOD
2H 241H 24FY24FY 23FY 24 vs.2H 24 vs.
FY 231H 24
$000$000$000$000
△
%
△
%
Operating revenue$10,812$13,095$23,907$19,61622%-17%
Total revenue$12,713$16,580$29,293$26,12412%-23%
Operating expenses$26,996$31,832$58,828$53,08911%-15%
Net Loss Before Tax-$14,283-$15,252-$29,535-$26,96510%-6%
Cash receipts from
customers
$10,561$13,576$24,137$18,46831%-22%
Net operating cash burn$10,758$14,992$25,750$25,5751%-28%
Net cash, cash equivalents
and short term deposits
$50,261$62,174$50,261$77,791-35%-19%

28
OPERATING EXPENSES FALL IN THE SECOND HALF
INVESTMENT NOW FOCUSSED ON LONG-TERM STRATEGIC INITIATIVES
•Operating expenses are up 11% for FY 24 vs FY 23.
•The 15%reductionin2H vs. 1H 24 isdue to theshift in
focus to preserve cashwhile enhancing clinical
evidence
oLaboratory operations largely driven by volume.
oResearchexpense is up42%in FY 24 vs FY 23 and
continued to increase 2H 24 vs 1H 24
demonstrating the importance placed on
strongclinical evidence, providing catalysts for
coverage.
oSales and marketing expense is up 2%FY 24 vs FY
23, but dropped 2H 24 vs 1H24 due to the
restructuring in late Q224.
oGeneral and administration expenses for FY 24
were down 7% on FY 23, with a decrease of 40%
2H 24 vs 1H 24 as initiatives to reduce cash burn
were implemented.
2H 241H 24FY24 FY 23FY 24 vs. 2H 24 vs.
FY 231H 24
$000$000$000$000
△
%
△
%
Laboratory operations $5,610$6,141$11,751$9,34926%-9%
Research$6,602$5,487$12,089$8,48442%20%
Sales and marketing $11,251$14,339$25,590$25,1232%-22%
General and administration$3,533$5,865$9,398$10,133-7%-40%
Total operating expenses$26,996$31,832$58,828$53,08911%-15%
FINANCIAL PERIOD

ESG, SUMMARY AND OUTLOOK.

30
ESG: PACIFIC EDGE IS FOUNDED ON IMPROVING SOCIAL OUTCOMES
1. Budgetary Impact of Including the Urinary Genomic Marker Cxbladder Detect in the Evaluation of Microhematuria Patients - PubMed (nih.gov)
2. Davidson, Peter; Presentation to Urofair, 2022, time to first specialist assessment.
Cxbladder delivers actionable information that can:
•Advance the standard of care that physicians offer to patients
•Improve patient experience, quality of life and healthcare outcomes
•Reduce the total cost of care for value-based or capitated healthcare systems
1,2
•Deliver healthcare equity to poorer and/or rural communities
•Improved access due to availability in primary care across New Zealand
2
•In Te Whatu Ora Canterbury, urological waiting lists fell by 25%
2
without compromising care
•Patients can receive a kit delivered to their home with in-home sampling
Mission
To help improve people’s lives and patient outcomes by
providing leading solutions for the early detection and
management of cancer
Vision
A world where the early diagnosis and better treatment of
cancer is within reach of everyone

31
ADVANCING SOCIAL, ENVIRONMENTAL AND GOVERNANCE GOALS
•SOCIAL
•Culture: High levels of staff engagement and participation in
development opportunities; active promotion of diversity,
inclusion and fair remuneration
•Human Rights: Major suppliers reviewed for compliance with
modern slavery and human rights policies
•Health and Safety: Zero lost time due to injuries
•ENVIRONMENTAL
•First year of mandatory reporting under the Aotearoa New
Zealand Climate Standards, delivered with FY24 as a baseline year
•Environmentally sustainable procurement policy introduced,
reflecting new sustainable purchasing requirements
•GOVERNANCE
•FMEA
1
risk management framework embedded across the
business with routine reporting
•Compliance with regulatory, quality, health & safety and
manufacturing standards in every country we operate in
WE:
Put patients first with everything we do
Are committed to customer success
Are transparent and trusting
Are guided by data & evidence
Support our teammates
We celebrate successes, large and small
1 – FMEA: Failure Mode and Effects Analysis

32
GOVERNANCE – DELIVERING PACIFIC EDGE STABILITY
MARK GREEN
Independent Director
CHRIS GALLAHER
Chairman
•Board notices of retirement announced in March 2024 to deliver stability:
•Chris Gallaher - appointed July 2016 - to retire from the Chair of
Pacific Edge following the appointment of a successor and a
structured handover later this year.
•Mark Green - appointed May 2021 - will not seek re-election to the
Board and will retire at the end of the Annual Shareholders Meeting
in September.
• The Board’s Nomination Committee has commenced a process to appoint
a new Chair and consider the recruitment of new Independent Directors.
AN ORDERLY SUCCESSION PROGRAM

SUMMARY AND OUTLOOK: READY FOR ALL OUTCOMES
•We expect to manage cash reserves if Medicare coverage is retained or until
re-coverage in the event of a negative determination.
•We will continue to:
•Focus our business on the clinical development for Detect
+
and Monitor
+

for guidelines inclusion and increased coverage certainty
•Focus our commercial operations on profitable territories, non-Medicare
revenue streams and cash collections
•Emphasize the clinical and economic value of Cxbladder in our sales
messaging
HEADWINDS:
•Possible non-coverage determination from Novitas on a new proposed LCD
after following appropriate ‘notice and comment’ procedure
•Possible negative physician or patient response to enhanced patient
responsibility on commercial insurance
CATALYSTS:
•Possible re-coverage determination from Novitas on new proposed LCD after
following appropriate procedure
•Cxbladder Detect
+
pricing (via Crosswalk) on 25 June 2024 CMS Meeting
•New clinical evidence for driving local coverage certainty
•Cxbladder Detect
+
commercial launch preparations
•Litigation success (in non-coverage scenario)
33

APPENDIX
34

PACIFIC EDGE: RESEARCH, INNOVATION, COMMERCIALIZATION
2001
2001
Pacific Edge
established
2007
2007
Commercial
pivot to
focus on
urothelial
cancer
diagnostics
2008
Holyoake et al:
Urine-based RNA
detection of
urothelial cancer.
Clin Cancer Res
2008
2011
2011
Pacific Edge
Diagnostics
New Zealand
(PEDNZ)
established
2012
2012
O’Sullivan et al:
Cxbladder Detect
performance
validation.
Journal of Urology
Dec 2012
Launch of Pacific Edge
Diagnostics USAand
Cxb Detect
2013
Mar 2013
PEDUSA receives
CLIA
accreditation
May 2013
First commercial
sale (Cxb Detect)
for PEDNZ
Mar 2013
First commercial
sale (Cxb Detect)
for PEDUSA
2014
Dec 2014
Launch of
Cxbladder
Triage
2015
Mar 2015
Kavalieris et al:
Cxb Triage
performance
validation. BMC
Urology
Dec 2015
Launch of
Cxbladder
Monitor
2016
Nov 2016
Clinical trials
commence in
Singapore
2018
Feb 2018
Cxb Triage
adopted into
Canterbury
Community Health
Pathways with
primary care
referral
2019
Aug 2019
Konety et al:
Clinical Utility of
Cxb Detect in
adjudicating
atypical cytology
and equivocal
cystoscopy.Europe
an Urology
2020
Apr 2020
Patient in-home
sampling initiated in
the US
Jun 2020
Kaiser Permanente,
approves commercial
use of Cxbladder
Jul 2020
CMS confirms
reimbursement of
Cxbladderat
$760/test
2021
Aug 2021
Cxbladder reaches
70% public
healthcare
coverage in NZ
Oct 2021
PEB raises
$103.5m
(~US$72.5m)
Dec 2021
First commercial
sale of Cxbladder
in Australia
2003
Listed on
the NZX
Cxbladder
TRIAGE
Cxbladder
DETECT
Cxbladder
MONITOR
2022
Dec 2022
Lotan et al:
Enhanced
Cxbladder
Tests Deliver
Improved
Performance.
Journal of
Urology
35
2023
Nov 2023
Kaiser
Permanente
EMR
integration
goes live
2024
May 2024
STRATA
podium
presentation
at AUA 2024.
Study
published in
Journal of
Urology

BLADDER CANCER
A SIGNIFICANT GLOBAL HEALTHCARE CHALLENGE
1. World Cancer Research Fund Annual case figure is 2020.
2. American Society of Clinical Oncology Annual death figure is 2020.
3. Average recurrence for low grade non-muscle invasive bladder cancer as published in Palou J et al (2012): Eur Urol 2012; 62: 118.
4. International Agency for Research on Cancer
36
10
th
Most common
cancer world-
wide
1
~70%
Recurrence
3
~573K
Annual cases
and growing
1
>212K
Annual
deaths
2
6
th
Most common
cancer in men
1
17
th
Most common
cancer in women
1
<1.7 1.7 to 2.7 2.7 to 5.3 5.3 to 8.6 >8.6
INCIDENCE PER 100,000 OF THE POPULATION
4

1. Pacific Edge estimates
USA – Total Addressable Market (TAM) US$3.5b
Americas (non-US) – TAM US$0.5b
EMEA (w/o most of Africa) – TAM US$1.4b
APAC (w/o China) – TAM US$2.2b
US$7.6b
Total
Addressable
Market
1
37
CXBLADDER IS A GLOBAL OPPORTUNITY
•US is the focus of our growth efforts
•New Zealand is a mature market
•APAC in business development
•Distribution considered in other markets
on a case-by-case basis
GLOBAL COMMERCIALIZATION

SUMMARY OF CLINICAL EVIDENCE
StudyPop. TypeSensitivity (Sn)NPVSpecificity (Sp)Comment
Detect+
AVLotan et al., 2022MH + GH*97%99.7%90%Pooled data from US and Singapore cohorts (n=804)
CV
DRIVE (unpublished) (1)MH + GH*Study in progress
AUSSIE (unpublished) (4)MH + GH*Study to start this year
microDRIVE (unpublished) (5)MH*Study to start this year
CUCREDIBLE (not started)(6)MHProtocol in final development stages, site selection starting by the end of year.
Triage
AVKavalieris et al., 2015MH + GH*95.10%98.50%45%Sn, Sp, NPV values when test-negative rate is 40%
CV
Davidson et al., 2019MH + GH*95.5% (1)98.6% (1)34.3%GH only: Sn (95.1%), NPV (98%), Sp (32.8%); MH only: Sn (100%), NPV (100%), Sp (42.6%)
Konety et al., 2019(2)100%
Cxbladder (3) correctly adjudicated all UC confirmed patients (n=26) with atypical urine cytology
results (n=153, 4)
Lotan et al., 2022MH + GH*89%99%63%Pooled data from US and Singapore cohorts (n=804)
CU
Davidson et al., 2020MH + GH*89.4% (5)98.9% (5)59% (5)
39% of patients testing negative for Cxb Triage & imaging did not get cystoscopy & were
managed at primary care (6)
Lotan et al., 2024 (7)MH + GH*90%99%56%
Showed clinicians using Triage undertook 59% fewer cystoscopies on low-risk patients
presenting with hematuria.
Detect
AVO'Sullivan et al., 2012GH*81.8%97%85.1%Cxb Detect detected 97% of HG tumors & 100% of Stage 1 or greater tumors
CV
Lotan et al., 2022MH + GH*74%97%82%Pooled data from US and Singapore cohorts (n=804)
DRIVE (unpublished) (1)MH + GH*Study in progress
Health
Economics
Tyson et al., 2023 MH
Published economic model shows significant savings for healthcare payers (median savings of
$559 in direct costs per patient)
Monitor
AVKavalieris et al., 2017(1)88% (2)97% (2)N/A(3)
CVKonety et al., 2019(4)100%
Cxbladder (5) correctly adjudicated all UC confirmed patients (n=26) with atypical urine cytology
results (n=153, 6)
CUKoya et al., 2020(7)
Integration of Cxb Monitor into the surveillance schedule reduced annual cystoscopies (39%)
(8,9)
CULi et al., 2023(7)
Cxbladder Monitor safely postpones a patient’s next scheduled cystoscopy, the current ‘gold
standard’ for bladder cancer surveillance
* Referred patients. Definitions - MH: Microhematuria, GH: Gross Hematuria. For Sensitivity, NPV and Specificity please see page 41 of this presentation
38

FOOTNOTES FOR CLINICAL EVIDENCE SUMMARY
Footnotes
Detect
+
1Observational study to validate performance characteristics and clinical utility of Cxbladder tests (Cxb Triage, Cxb Detect, Cxb Detect
+
).
2Observational study to validate performance characteristics of Cxb Detect
+
in patients with UC of the upper tract.
3Patients with suspected upper tract UC (UTUC) or surveillance patients with a history of UTUC.
4Observational study to validate performance characteristics and clinical utility of Cxbladder tests (Cxb Triage, Cxb Detect, Cxb Detect
+
).
5Observational study to validate performance characteristics of Cxb Detect
+
in microhematuria (MH) patients.
6Clinical utility study comparing the reduction of cystoscopy use when implementing the new clinical pathway to SOC in a defined MH population.
Triage
1Cxb Triage performance; Cxb Triage & imaging combined performance had a Sn of 97.7% & NPV of 99.8%.
2Patients included hematuria evaluation (n=436) or surveillance previously diagnosed with UC (n=416) with both Cxbladder & urine cytology results.
3Cxbladder includes Cxbladder Triage & Cxbladder Monitor.
4This included n=70 for patients with hematuria & n=83 for patients with previously diagnosed UC and overall test negative rate of 30.7%.
5Cxb Triage performance; Cxb Triage & imaging combined performance had a Sn of 98.1%, NPV of 99.9% & Sp of 98.4%.
6Cxb Triage negative rate was 53%; Follow-up period of 21-months showed no missed cancers, demonstrating safety.
7Cxb Triage demonstrated to have clinical utility in safely risk stratifying low risk microhematuria patients and not undertake cystoscopy.
Detect
1
Observational study to validate performance characteristics and clinical utility of Cxbladder tests (Cxb Triage, Cxb Detect, Cxb Detect
+
).
Monitor
1Surveillance patients previously diagnosed with primary or recurrent UC.
2Cxb Monitor performance characteristics on surveillance patients diagnosed with primary UC; Cxb Monitor had a Sn of 93% and NPV of 94% on patients with recurrent UC.
3Using Kavalieris et al., (2017) data set, Lotan et al., (2017) compared relative performance of Cxb Monitor against NMP22 ELISA, NMP22 BladderChek and urine cytology.
4Patients included hematuria evaluation (n=436) or previously diagnosed UC (n=416) with both Cxbladder & urine cytology results.
5Cxbladder includes Cxbladder Triage & Cxbladder Monitor.
6This included n=70 for patients with hematuria & n=83 for patients with previously diagnosed UC; test negative rate of 30.7%.
7All patients were being evaluated for recurrence of UC (n=309 providing 443 samples).
8Cxb Monitor identified all seven confirmed recurrence events idnetified on the first cystoscopy.
9Patients returning negative Cxb Monitor results (n=235) had no pathology-confirmed recurrence at 1st cystoscopy
39

REFERENCES SUMMARY OF CLINICAL EVIDENCE
References
Detect
+
Lotan et al., (2022). Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification.The Journal of Urology, 10-1097.
Triage
Davidson et al., (2019). Inclusion of a molecular marker of bladder cancer in a clinical pathway for investigation of haematuria may reduce the need for cystoscopy.NZ Med J,132(1497), 55-64.
Davidson et al., (2020). Assessment of a clinical pathway for investigation of haematuria that reduces the need for cystoscopy.The New Zealand Medical Journal (Online),133(1527), 71-82.
Kavalieris et al., (2015). A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage outpatients presenting with hematuria who
have a low probability of urothelial carcinoma.BMC urology,15(1), 1-12.
Konety et al., (2019). Evaluation of cxbladder and adjudication of atypical cytology and equivocal cystoscopy.European urology,76(2), 238-243.
Lotan et al., (2022). Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification.The Journal of Urology, 10-1097.
Lotan et al. (2024) . A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria. The Safe Testing of Risk for Asymptomatic
Microhematuria Trial. (In Press) The Journal of Urology Vol 212 1-8 Jul 2024.
Detect
Lotan et al., (2022). Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification.The Journal of Urology, 10-1097.
O'Sullivan et al., (2012). A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria.The Journal of urology,188(3), 741-747.
Monitor
Kavalieris et al., (2017). Performance characteristics of a multigene urine biomarker test for monitoring for recurrent urothelial carcinoma in a multicenter study.The Journal of Urology,197(6), 1419-1426.
Konety et al., (2019). Evaluation of cxbladder and adjudication of atypical cytology and equivocal cystoscopy.European urology,76(2), 238-243.
Koya et al., (2020). An evaluation of the real-world use and clinical utility of the Cxbladder Monitor assay in the follow-up of patients previously treated for bladder cancer.BMC urology,20(1), 1-9.
Lotan et al., (2017). Clinical comparison of non-invasive urine tests for ruling out recurrent urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 35 (8), 531-539.
Li et al., (2023). Cxbladder Monitor testing to reduce cystoscopy frequency in patients with bladder cancer. Urologic Oncology: Seminars and Original Investigations, 41 (7), 326.e1 – 326.38.
40

GLOSSARY
•Sensitivity (Sn) - the frequency with which a test correctly identifies patients with a disease.
•Specificity (Sp) - the frequency with which a test correctly identifies patients without a disease.
•Negative Predictive Value (NPV) - the percentage of negative tests being true negatives (by standard of care).
•Positive Predictive Value (PPV) - the percentage of positive tests being true positives (by standard of care).
•Rule-out Rate (ROR) - the percentage of tests that return a negative result.
•Evidence definitions:
•Analytical validity (AV): Evidence that a test is repeatable in the lab for a given indication and population.
•Clinical validity (CV): Evidence a test works in the same way on an independent eligible population for a given indication.
•Clinical utility (CU): Evidence that a test in the hands of a physician can usefully change patient management within the context
of care for the defined population and indication.
41

INDEPENDENT DIRECTORS
SARAH PARK
ANATOLE MASFEN
BRYAN WILLIAMS
ANNA STOVE
MARK GREEN
TONY BARCLAY
CHRIS GALLAHER
Chairman
Chris has held senior positions in
both CEO and CFO roles with large
international companies and was a
partner in Arthur Young, Chartered
Accountants. Prior to retiring from
full time corporate life, he was CFO
of Fulton Hogan, a large New
Zealand civil contractor
DR PETER MEINTJES
Chief Executive Officer
Peter is a molecular diagnostics and
genomics leader focused on
nascent market development of
disruptive innovations to drive
commercial success. Prior to joining
Pacific Edge, he was based in
Boston in a succession of diagnostic
leadership roles. Most recently he
was the Chief Commercial Officer
at Eurofins Transplant Genomics
and before that he was CEO at
Omixon
SENIOR LEADERSHIP TEAM
GRANT GIBSON DAVID LEVISON DR TAMER ABOUSHWAREB
Chief Financial Officer President Pacific Edge Diagnostics USA Chief Medical Officer
GLEN COSTIN DARELL MORGAN DR JUSTIN HARVEY
President Asia Pacific Chief Operating Officer Chief Technology Officer
ANDY MCINTOSH PROFESSOR PARRY GUILFORD
Chief Digital Officer Chief Scientific Officer
PACIFIC EDGE BOARD AND MANAGEMENT
42

FOR MORE INFORMATION:
Dr. Peter Meintjes
Chief Executive Officer
email: peter.meintjes@pelnz.com
Grant Gibson
Chief Financial Officer
email: grant.gibson@pelnz.com
Pacific Edge
87 St David Street, PO Box 56, Dunedin, New Zealand
P +64 3 577 6733 Within NZ 0800 555 562
email: investors@pacificedge.co.nz
www.pacificedgedx.com
43

---

24
CONSOLIDATED
FINANCIAL
STATEMENTS
FOR THE YEAR ENDED
31 MARCH 2024

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
2
Consolidated Financial Statements
Consolidated Statement of Comprehensive Income 3
Consolidated Statement of Changes in Equity 4
Consolidated Balance Sheet 5
Consolidated Statement of Cash Flows 6
Notes to the Consolidated Financial Statements 7
Independent Auditor’s Report 37
Company Directory 42

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
3
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
For the year ended 31 March 2024
Note: These Consolidated Financial Statements are to be read in conjunction with the Notes to the Consolidated Financial Statements
Notes
2024
($000)
2023
($000)
REVENUE
Operating Revenue 5 23,907 19,616
Total Operating Revenue 23,907 19,616
Other Income5 1,322 1,417
Interest Income9 3,433 2,761
Foreign Exchange Gain 631 2,330
Total Revenue and Other Income 29,293 26,124
OPERATING EXPENSES
Laboratory Operations11,751 9,349
Research612,089 8,484
Sales and Marketing25,590 25,123
General and Administration79,398 10,133
Total Operating Expenses58,828 53,089
NET LOSS BEFORE TAX(29,535) (26,965)
Income Tax Expense16 - -
LOSS FOR THE YEAR AFTER TAX(29,535) (26,965)
Items that may be reclassified to profit or loss:
Translation of Foreign Operations 142 (99)
Disposal of Foreign Operation (20)-
TOTAL COMPREHENSIVE LOSS attributable to
equity holders of the Company
(29,413) (27,064)
Earnings per share for loss attributable to the equity
holders of the Company during the year
Basic and Diluted Earnings per share3 (0.036) (0.033)

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
4
Share
Capital
Accumulated
Losses
Share
Based
Payments
Reserve
Foreign
Currency
Translation
Reserve
Total
Equity
Notes($000)($000)($000)($000)($000)
Balance as at 31 March 2022 294,139 (189,849) 3,145 941 108,376
Loss after tax - (26,965) - - (26,965)
Other Comprehensive Income - - - (99) (99)
TOTAL COMPREHENSIVE LOSS
attributable to equity holders of the
Company
- (26,965) - (99) (27,064)
Transactions with owners in their
capacity as owners:
Issue of Share Capital18 (4) - - - (4)
Share Based Payments- Employee
Remuneration
8 182 - - - 182
Share Based Payment- Employee
Share Options
8 - - 1,273 - 1,273
Balance as at 31 March 2023 294,317 (216,814) 4,418 842 82,763
Balance as at 31 March 2023 294,317 (216,814) 4,418 842 82,763
Loss after tax - (29,535) - - (29,535)
Other Comprehensive Income - - - 122 122
TOTAL COMPREHENSIVE LOSS
attributable to equity holders of the
Company
- (29,535) - 122 (29,413)
Transactions with owners in their
capacity as owners:
Share Based Payments- Employee
Remuneration
8 83 - - - 83
Share Based Payment- Employee
Share Options
8 - - 1,189 - 1,189
Balance as at 31 March 2024 294,400 (246,349) 5,607 96454,622
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
For the year ended 31 March 2024
Note: These Consolidated Financial Statements are to be read in conjunction with the Notes to the Consolidated Financial Statements

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
5
CONSOLIDATED BALANCE SHEET
As at 31 March 2024
Notes
2024
($000)
2023
($000)
CURRENT ASSETS
Cash and Cash Equivalents9 29,261 33,229
Short Term Deposits9 21,000 44,562
Receivables10 4,698 5,493
Inventory11 1,688 1,287
Other Assets12 1,228 1,400
Total Current Assets 57,875 85,971
NON-CURRENT ASSETS
Property, Plant and Equipment13 2,925 2,768
Right of Use Assets23 3,698 1,143
Intangible Assets14 950 1,031
Total Non-Current Assets 7,573 4,942
TOTAL ASSETS 65,448 90,913
CURRENT LIABILITIES
Payables and Accruals176,753 6,928
Borrowings 300 -
Lease Liabilities23 1,264 811
Total Current Liabilities8,317 7,739
NON-CURRENT LIABILITIES
Lease Liabilities23 2,509 411
Total Non-Current Liabilities 2,509 411
TOTAL LIABILITIES10,826 8,150
NET ASSETS54,622 82,763
Represented by:
EQUITY
Share Capital18294,400 294,317
Accumulated Losses(246,349) (216,814)
Share Based Payments Reserve 5,607 4,418
Foreign Translation Reserve964 842
TOTAL EQUITY 54,622 82,763
FURTHER INFORMATION
Net Tangible Assets per share ($) 0.066 0.101
For and on behalf of the Board of Directors dated the 20th day of May 2024:
Director Director
Note: These Consolidated Financial Statements are to be read in conjunction with the Notes to the Consolidated Financial Statements

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
6
CONSOLIDATED STATEMENT OF CASH FLOWS
For the year ended 31 March 2024
Notes
2024
($000)
2023
($000)
CASH FLOWS TO OPERATING ACTIVITIES
Cash was provided from:
Receipts from Customers 24,137 18,468
Receipts from Grant Providers 1,856 1,066
Interest Received 3,441 2,716
29,434 22,250
Cash was disbursed to:
Payments to Suppliers and Employees55,196 47,869
Net GST (inflow) (12) (44)
55,184 47,825
Net Cash Flows To Operating Activities20(25,750) (25,575)
CASH FLOWS FROM INVESTING ACTIVITIES:
Cash was provided from:
Proceeds from Short Term Deposits 83,084 143,490
83,084 143,490
Cash was disbursed to:
Purchase of Short Term Deposits 59,523 118,107
Capital Expenditure on Plant and Equipment 832 1,870
Capital Expenditure on Intangible Assets 540 1,039
60,895 121,016
Net Cash Flows From Investing Activities 22,189 22,474
CASH FLOWS TO FINANCING ACTIVITIES:
Cash was provided from:
Proceeds from Borrowings 300 -
Ordinary Shares Issued18 - (4)
300 (4)
Cash was disbursed to:
Repayment of Leases- Principal23 1,268 1,195
Repayment of Leases- Interest23 138 83
1,406 1,278
Net Cash Flows To Financing Activities (1,106) (1,282)
Net (Decrease) in Cash Held(4,667) (4,383)
Add Opening Cash Brought Forward 33,229 35,412
Effect of exchange rate changes on net cash699 2,200
Ending Cash Carried Forward929,261 33,229
Note: These Consolidated Financial Statements are to be read in conjunction with the Notes to the Consolidated Financial Statements

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
7
Notes to the Consolidated Financial Statements
For the year ended 31 March 2024
1. MATERIAL ACCOUNTING POLICY INFORMATION
Reporting Entity
The consolidated financial statements (hereafter referred to as the ‘financial statements’) presented for the year
ended 31 March 2024 are for Pacific Edge Limited (the ‘Company’) and its subsidiaries (collectively referred to as
the ‘Group’). The Group’s purpose is to research, develop and commercialise new diagnostic and prognostic tools
for the early detection and management of cancers.
Pacific Edge Limited is registered in New Zealand under the Companies Act 1993 and is a Financial Markets
Conduct (FMC) reporting entity under Part 7 of the Financial Markets Conduct Act 2013. The financial statements
of the Group have been prepared in accordance with the requirements of the Financial Markets Conduct Act 2013
and the NZX Listing Rules. The financial statements presented are those of the Group, consisting of the Parent
entity, Pacific Edge Limited and its subsidiaries. The Company is dual listed, with its primary listing of ordinary
shares quoted in New Zealand on the NZX Main Board, and a secondary listing in Australia as a Foreign Exempt
Entity on the ASX.
These financial statements have been approved for issue by the Board of Directors on the 20th May 2024.
Basis of Preparation
These financial statements of the Group have been prepared in accordance with Generally Accepted Accounting
Practice in New Zealand (NZ GAAP). The Group is a for-profit entity for the purposes of complying with NZ GAAP.
The financial statements comply with New Zealand equivalents to International Financial Reporting Standards
(NZ IFRS), other New Zealand accounting standards and authoritative notices that are applicable to entities that
apply NZ IFRS. The financial statements also comply with International Financial Reporting Standards Accounting
Standards (“IFRS Accounting Standards”) as issued by the IASB.
The financial statements are presented in New Zealand Dollars, which is the Company’s functional currency and
Group’s presentation currency, and all values are rounded to the nearest thousand dollars ($000). The accounting
principles recognised as appropriate for the measurement and reporting of earnings, cash flows and financial
position on a historical cost basis have been used.
The Consolidated Statement of Comprehensive Income and Consolidated Statement of Cash Flows have been
prepared so that all components are stated net of GST. All items in the Consolidated Balance Sheet are stated net
of GST, with the exception of receivables and payables.
Management of Capital
The capital structure of the Group consists of equity raised by the issue of ordinary shares in the Company.
The Company’s objectives when managing capital are to safeguard the Company’s ability to continue as a going
concern in order to provide returns for shareholders, provide benefit for other stakeholders and to maintain an
optimal capital structure to support the development of its business. The Company meets these objectives through
closely managing revenue and expenditure, and where required issues new shares.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
8
Notes to the Consolidated Financial Statements
For the year ended 31 March 2024
Basis of Consolidation
The following entities and the basis of their inclusion for consolidation in these Financial Statements are as follows:
Name of Subsidiary
Place of
Incorporation
(or registration)
& Operation
Principal Activity
Ownership Interests
& Voting Rights
31 March
2024
%
31 March
2023
%
Pacific Edge Diagnostics
New Zealand Limited
New Zealand
Commercial Sales and Diagnostic
Laboratory Operation
100100
Pacific Edge (Australia) Pty
Limited
Australia
Commercial Sales and
Biotechnology Research
& Development
100100
Pacific Edge Diagnostics USA
Limited
USA
Commercial Sales and Diagnostic
Laboratory Operation
100100
Pacific Edge Diagnostics
Singapore Pte Limited
Singapore
Commercial Sales and
Biotechnology Research
& Development.
In the process of being
dissolved as at 31 March 2024
100100
Pacific Edge Analytical Services
Limited
New ZealandDormant Company100100
The financial statements incorporate the assets, liabilities and results of all subsidiaries of Pacific Edge Limited as at
31 March 2024 and for the year then ended. All subsidiaries have the same balance date as the Company of 31 March.
Pacific Edge Limited consolidates all entities over which Pacific Edge Limited has control. Control is achieved when
the Group:
• has power to direct the activities of the entity;
• is exposed, or has rights, to variable returns from involvement with the entity; and
• has the ability to use its power to affect its returns.
Subsidiaries which form part of the Group are consolidated from the date on which control is transferred to the
Group. They are de-consolidated from the date that control ceases.
The acquisition method of accounting is used to account for business combinations by the Group. The consideration
transferred for the acquisition of a subsidiary is the fair value of the assets transferred, the liabilities incurred and the
equity interest issued by the Group.
The consideration transferred includes the fair value of any asset or liability resulting from a contingent consideration
arrangement. Acquisition-related costs are expensed as incurred. Identifiable assets acquired and liabilities and
contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition
date. On an acquisition-by-acquisition basis, the Group recognises any non-controlling interest in the acquiree either
at fair value or at the non-controlling interest’s proportionate share of the acquiree’s net assets. Inter-company
transactions, balances and unrealised gains on transactions between Group companies are eliminated. Unrealised
losses are also eliminated. Accounting policies of subsidiaries have been changed where necessary to ensure
consistency with the policies adopted by the Group.
Critical Accounting Estimates and Assumptions
In preparing these financial statements, the Group made estimates and assumptions concerning the future.
These estimates and assumptions may differ from the subsequent actual results. Estimates and assumptions are
continually evaluated and are based on historical experience and other factors including expectations or future
events that are believed to be reasonable under the circumstances.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
9
Notes to the Consolidated Financial Statements
For the year ended 31 March 2024
The Group has performed an assessment of potential climate related risks and considered the location of
laboratories and other key operations in each region that it operates in and concluded that there is no material
impact on the current financial statements.
All other material accounting policy information has been applied on a basis consistent with those used in the
audited financial statements of Pacific Edge Limited for the year ended 31 March 2023.
2. NEW STANDARDS
NEW DISCLOSURE REQUIREMENTS AND CHANGES IN ACCOUNTING STANDARDS ADOPTED BY THE GROUP
On 14 December 2022 the External Reporting Board (XRB) published its climate-related disclosure standard. The
mandatory reporting regime is for reporting periods beginning after 1 January 2023. Climate-related disclosures
will be reported at the time of issuance of the Annual Report.
There are other no new disclosures, standards or interpretations material to the Group to be applied during the
year.
NEW STANDARDS AND INTERPRETATIONS NOT YET ADOPTED BY THE GROUP
The following new accounting standards and interpretations have been published that are not mandatory for
31 March 2024 reporting periods and have not been early adopted by the Group.
IFRS 18 Presentation and Disclosure in Financial Statements (IFRS 18)
IFRS 18 Presentation and Disclosure in Financial Statements (IFRS 18) was issued in April 2024 as replacement for
IAS 1 Presentation of Financial Statements (IAS 1). Most of the presentation and disclosure requirements would
largely remain unchanged together with other disclosures carried forward from IAS 1 IFRS 18 primarily introduces
the following:
• a defined structure for the consolidated statement of comprehensive income by classifying items into one
of the five categories: operating, investing, financing, income taxes and discontinued operations. Entities will
also present expenses in the operating category by nature, function, or a mix of both, based on facts and
circumstances
• disclosure of management-defined performance measures non-GAAP measures in a single note together with
reconciliation requirements, and
• additional guidance on aggregation and disaggregation principles (applied to all primary financial statements
and notes).
IFRS 18 also made limited change to certain presentation and disclosure requirements in the financial statements;
as well as consequential changes to various IFRS Accounting Standards.
IFRS 18 will be effective for annual reporting periods beginning on or after 1 January 2027 and entities could
early adopt this accounting standard. The Group expects to adopt IFRS 18 and relevant consequential changes of
other accounting standards in the 2028 financial statements. The Group is currently assessing the impact and will
disclose more detailed assessments in the future.
Disclosure of Fees for Audit Firms’ Services (Amendments to FRS-44)
The amendments to FRS-44 aim to address concerns about the quality and consistency of disclosures an entity
provides about fees paid to its audit firm for different type of services.
Application of this amendment is required for accounting periods beginning on or after 1 January 2024. The Group
expects to adopt amendments to FRS-44 in the 2025 financial statements. The Group is currently assessing the
impact and will disclose more detailed assessment in the future.
There are no other NZ IFRS or NZ IFRIC interpretations that are not yet effective that would be expected to have a
material impact on the Group.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
10
Notes to the Consolidated Financial Statements
For the year ended 31 March 2024
3. EARNINGS PER SHARE
(a) Basic
Basic earnings per share is calculated by dividing the profit (or loss) attributable to equity holders of the Company
by the weighted average number of ordinary shares on issue during the year excluding ordinary shares purchased
by the Company (Note 18).
GROUP
2024
($000)
2023
($000)
Loss attributable to equity holders of the Company(29,535) (26,965)
Weighted average number of ordinary shares on issue 810,727 810,226
Earnings per share (0.036) (0.033)
(b) Diluted
Diluted earnings per share is calculated by adjusting the weighted average number of shares outstanding to
assume conversion of all dilutive potential ordinary shares. The Group’s dilutive potential ordinary shares are in the
form of share options. As the Group made a loss during the current year and losses cannot be diluted, basic and
diluted earnings per share are the same.
4. LABORATORY THROUGHPUT AND COMMERCIAL TESTS –
NON-GAAP REPORTING
Laboratory Throughput is a key metric for the Group: Laboratory Throughput provides evidence of the usage
of Cxbladder products globally and the rates of adoption between different customer segments. The inclusion
of this non-GAAP reporting is considered helpful to readers of these financial statements, as it allows readers
to compare the current period to prior periods and assess usage trends on a consistent basis. Total laboratory
throughput includes commercial tests, which are invoiced to customers (including tests for patients covered by
the US government’s medical program through the Centers for Medicare and Medicaid Services (CMS)), and
tests which are not considered to be commercial as these tests relate to Research Tests or other non-chargeable
activities.
Commercial Test numbers are also a key metric for the Group: Commercial Tests are those tests for which the
Company is actively seeking reimbursement and cash receipts, and tests performed at no charge in order to
gain new customers. The inclusion of this non-GAAP reporting is considered helpful to readers of these financial
statements as it allows readers to compare the current period to prior periods and assess trends on a consistent
basis.
Laboratory Throughput and Commercial Tests per financial year are shown below.
FY24FY23
Total Laboratory Throughput (tests) 32,633 31,565
Increase in Total Laboratory Throughput (%) 3%37%
Increase in Throughput from previous year (tests) 1,068 8,479
Total Commercial Tests (tests) 27,347 26,691
Increase in Commercial Tests from previous year (%)2%39%
Increase in Commercial Tests from previous year (tests) 656 7,495
Commercial Tests as a percentage of Total Laboratory
Throughput (%)
84%85%

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
11
Notes to the Consolidated Financial Statements
For the year ended 31 March 2024
5. REVENUE
Background information on US customers and the payment process
A physician orders a Cxbladder test when a patient presents to their clinic with symptoms that indicate the
possibility of bladder cancer. The most common and significant symptom is haematuria or blood in their urine.
A urine sample is collected from the patient and sent in the Cxbladder Urine Sampling System to the Group’s
laboratory in the US or in New Zealand. The Group receives and processes the urine sample and returns the results
of the test back to the ordering physician. The individual patient is the Group’s customer, however typically in the
US market, the patient’s insurer may pay the Group for some or all of the cost of the test.
When a physician orders a Cxbladder test, the Group has an obligation to perform the test and report the results to
the ordering physician irrespective of the patient’s insurance contract. A patient may have private insurance cover,
be covered by the US government’s medical program through CMS or have no insurance cover.
Once the Cxbladder test has been completed, all information required for insurance purposes is sent to the Group’s
billing and reimbursement agent to begin the process to collect reimbursement from any applicable insurance
companies for the Cxbladder test performed.
For patients with private insurance cover, the relevant patient and test order information will be sent to their
insurance provider. When the Group does not have an individual agreement with that insurance provider to pay
for Cxbladder tests (“out of network”), the insurance provider will assess that individual patient’s test for medical
necessity and the level of insurance cover (if any) available to cover the cost of the test. This process of assessment
can take many months to work through before the Group receives payments (if any) from the insurance company.
The Group does have agreements with some insurance providers but these currently cover a small proportion of
the Group’s customers.
For patients covered by CMS, invoices are sent to CMS. Prior to 3 July 2020, Pacific Edge was not included in the
Local Coverage Determination (LCD) and as a result, did not normally receive any amounts for tests performed
for patients covered by CMS. On 3 July 2020, Pacific Edge received notice of inclusion in the LCD, resulting in
the Company receiving reimbursement for Cxbladder Monitor and Detect tests performed after 1 July 2020 for
patients covered by the CMS across the US that are deemed medically necessary.
For uninsured patients, the Group has no certainty of when or if the patient will pay.
Refer to note 25 for details on the proposed Local Coverage Determination change that has the potential to
negatively impact future revenue.
Rest of World Customers
Revenue from Rest of World customers is primarily from Te Whatu Ora Health New Zealand. In all Rest Of World
locations, there is a clearly defined contract with the customer meeting the requirements of NZ IFRS 15. Pacific
Edge Diagnostics New Zealand Limited has individual contracts with regions across New Zealand and revenue is
recognised as described on the following pages.
Critical Accounting Estimate
The application of NZ IFRS 15: Revenue from contracts with customers (NZ IFRS 15) requires the application of
significant judgement in determining whether the Group meets the five key criteria identified in NZ IFRS 15, which
must be met before revenue may be recognised as performance obligations are satisfied. For the Group this would
result in some revenue recognised in advance of the receipt of cash.
The significant judgements adopted by the Group relate to :
- determining if a contract with the customer exists;
- identifying the rights of each party;
- identifying the payment terms;
- ensuring the contract has commercial substance; and
- determining whether it is probable that the Group will collect the consideration to which it is entitled.
While there has been significant judgement applied to all five criteria, there are two criteria that have higher levels
of uncertainty, requiring increased levels of judgement. The significant judgements applied to determine the
Transaction Price and determining the probability of collecting consideration are detailed in the Accounting Policy
relating to Revenue from Cxbladder Tests.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
12
Notes to the Consolidated Financial Statements
For the year ended 31 March 2024
ACCOUNTING POLICY
Revenue from Cxbladder tests – USA
The Group performs Cxbladder tests when requested by a patient’s physician. At the point the test results are
returned to the physician, the Group has satisfied its performance obligation and has the right to issue an invoice.
On return of the test result, the Group has determined a contract exists, that the payment terms are identified, that
the contract has commercial substance and there has been identification of the rights of each party.
On the 3 July 2020, Pacific Edge received notice of inclusion in the LCD, resulting in the Company receiving
reimbursement for Cxbladder Monitor and Detect tests performed after 1 July 2020 for patients covered by
the CMS across the US that are deemed medically necessary. Reimbursement for these tests is at the already
determined national CMS price for Cxbladder of US$760 per test, less a 2% sequestration fee.
Since Cxbladder’s inclusion in the LCD, based on historical data, the Group has been able to reliably estimate
both the probability and size of payment received from the CMS. The inclusion within the LCD combined with the
growing support for the use of Cxbladder within the US has also allowed the Group to reliably estimate both the
probability and size of payment received from customers covered by Medicare Advantage policies provided by
private insurers and customers covered by Kaiser Permanente.
Tests performed for patients covered by other private policies, or tests performed for those with no insurance
cover continue to be recognised as revenue when cash is received due to not being able to reliably estimate both
probability and size of payment received.
The Group have concluded that the contracts with the CMS and customers covered by Medicare Advantage and
Kaiser Permanente include variable consideration because the amounts paid by Medicare, Kaiser Permanente or
the commercial health insurance carriers that provide Medicare Advantage may be paid at less than our standard
rates or not paid at all, with such differences considered implicit price concessions. Variable consideration
attributable to these price concessions is measured at the expected value, and are determined by historical average
collection rates by test type and payor category taking into consideration the range of possible outcomes and
predictive value of our past experiences. Such variable consideration is included in the transaction price only to the
extent it is probable that a significant reversal in the amount of cumulative revenue recognised will not occur.
As a result of the Significant Judgements applied, the Group have determined the criteria under NZ IFRS 15 which
allows revenue to be recognised in advance of the receipt of cash have been met, and the Group has recognised
revenue for tests which were performed from 1 October 2023 to 31 March 2024 (6 months prior to balance date)
for which payment has not been received by 31 March 2024 from CMS and Medicare Advantage. Following a
change in commercial agreement, revenue for Kaiser Permanente is recognised in the month the test is performed.

Rest of World revenue recognition from tests performed
There has been no change in accounting policy or estimates for Operating Revenue for the Rest of World. The
Group performs Cxbladder tests when requested by a patient’s physician in New Zealand, Australia and Southeast
Asia. At the point the test results are returned to the physician, the Group has satisfied its performance obligations
have been met. At the end of the month an invoice is issued to the customer based on the number of tests
performed. Revenue is recognised when the invoice is issued.
OTHER INCOME
Grant Income
Government Grants are not recognised until there is reasonable assurance that the Group will comply with the
conditions attached to them and that the grants will be received. Government Grants are recognised in Other
Income in the consolidated statement of comprehensive income, on a systematic basis over the periods in which
the Group recognises the related costs as expenses for which the grants are intended to compensate.
The Company receives grants from Callaghan Innovation for postgraduate internships and summer students.
All conditions of the grants have been complied with.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
13
Notes to the Consolidated Financial Statements
For the year ended 31 March 2024
Research Rebates and Tax Incentives
- New Zealand R&D Tax Incentive (RDTI)
The New Zealand RDTI is a 15% tax credit on the money invested in eligible research and development (R&D) that
has occurred in New Zealand. As the New Zealand companies are in a tax loss position, the Group is eligible for the
Tax Incentive to be refunded.
The RDTI is recognised at its fair value where there is a reasonable assurance that the credit will be received and
the Group will comply with all attached conditions.
All conditions of the New Zealand RDTI have been complied with. Payment will be received after submission of
each annual research and development tax claim.
- Australia Cxbladder Research Rebate
A Cxbladder research programme is administered by Pacific Edge (Australia) Pty Limited and tax rebates are
received as a result of this programme.
The Cxbladder research rebate is recognised at its fair value where there is a reasonable assurance that the rebate
will be received and the Group will comply with all attached conditions.
For the year ended 31 March 2024, Group revenue is over $20m Australian Dollars, resulting in research rebates
being issued as a tax credit instead of a cash payment as received for the year ended 31 March 2023. As the
Group made a loss for period, this change results in the research rebate not being recognised as a tax credit in the
financial statements for the year ended 31 March 2024.

REVENUE AND OTHER INCOME
2024
($000)
2023
($000)
Cxbladder Sales
– US - Accrual Accounting 19,288 16,362
– US - Cash Accounting 3,214 2,388
– Total US Sales 22,502 18,750
– Rest Of World 1,405 866
Total Operating Revenue 23,907 19,616
Other Income
Grant Revenue 24 44
Research Rebates and Tax Incentives 1,298 1,373
Total Other Income 1,322 1,417

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
14
Notes to the Consolidated Financial Statements
For the year ended 31 March 2024
6. RESEARCH AND DEVELOPMENT COSTS
ACCOUNTING POLICY
Research is the original and planned investigation undertaken with the prospect of gaining new scientific
knowledge and understanding. This includes: direct and overhead expenses for diagnostic and prognostic
biomarker discovery and research; pre-clinical trials; and costs associated with clinical trial activities. All research
costs are expensed when incurred.
Development is the application of research findings to a plan or design for the production of new or substantially
improved processes or products prior to the commencement of commercial production.
When a project reaches the stage where it is probable that future expenditure can be recovered through the
process or products produced, expenditure that is directly attributed or reasonably allocated to that project is
recognised as a development asset within intangible assets. If the expenditure also benefits processes or products
for which it cannot be recovered, it will be expensed. The asset will be amortised from the date of commencement
of commercial production of the product to which it relates on a straight-line basis over the period of expected
benefit. Development assets are reviewed annually for any impairment in their carrying value.
GROUP
Notes
2024
($000)
2023
($000)
Research Expenses12,089 8,484
Includes:
Employee Benefits86,571 4,930
7. GENERAL AND ADMINISTRATION EXPENSES
GROUP
Notes
2024
($000)
2023
($000)
Amortisation14 311 213
Auditors Remuneration: PricewaterhouseCoopers New Zealand
- Group year end financial statements
- Half year review of financial statements
- Singapore Statutory financial statements
194
34
-
184
30
12
Auditors Remuneration: PricewaterhouseCoopers Singapore
- Statutory financial statements - 15
Other services provided by PricewaterhouseCoopers New Zealand
- Corporate Treasury and Financial Modeling Workshops2-
Depreciation13 358 263
Depreciation on Right of Use Assets23 195 187
Directors Fees22 500 495
Employee Benefits83,974 4,990
Insurance 610 501
Interest on Lease Liabilities23 21 13
Legal Fees 826 692
NZX, ASX and Registry Fees 274 305
Other Operating Expenses2,099 2,233
9,398 10,133
Note: Amounts displayed for Amortisation, Depreciation, Employee Benefits are only the General and Administration Expenses
component of the total expenses. Refer to relevant notes for full expense disclosure.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
15
Notes to the Consolidated Financial Statements
For the year ended 31 March 2024
Other Operating Expenses
The major categories of expenditure which make up General and Administration Expenses, but are not disclosed
separately above are Information Technology costs, Compliance and Regulatory costs, Investor Relations costs,
Consultants and Contractors.
8. EMPLOYEE BENEFITS
GROUP
Notes
2024
($000)
2023
($000)
Represented by:
Employee Benefits:
Lab Operations 3,1192,480
Research66,5714,930
Sales and Marketing16,69715,155
General and Administration73,9744,990
Total Employee Benefits30,36127,555
Employee Share Scheme
The Company has an Employee Share Scheme where ordinary shares in the Company may be issued to selected
employees to recognise performance or a significant contribution to the Company. These shares may be issued
in lieu of a cash bonus or in addition to the employee’s remuneration. The ordinary shares are issued directly to
the employee and the Company accounts for the cost of the shares. The shares are allocated to the employee on
the date that the Board approves the issue of the share capital. All employees who hold ordinary shares in the
Company must comply with the Company’s Share Trading Policy.
The issuance of ordinary shares to employees is treated as equity settled share-based payments. Equity-settled
share-based payments to employees are measured at the fair value of the equity instruments at the grant date
based on the market price at the time of issuance. The fair value of shares granted is recognised as an employee
expense in the Consolidated Statement of Comprehensive Income when the shares are issued. During the 2024
financial year, 906,000 (2023: 278,000) ordinary shares were issued to employees as part of the Employee Share
Scheme. The associated non-cash cost of these shares was $83,000 (2023: $182,000). Refer to Note 18 for further
details on the shares issued during the financial year.
Attract and Retain Options
The Board believes that the issue of share options provides an appropriate incentive for participating employees to
grow the total shareholder return of the Company.
Attract and retain options are issued to selected employees as a long-term component of remuneration in
accordance with the Group’s remuneration policy. Incentive Options entitle the holder, on payment of the exercise
price, to one ordinary share of the Company.
The exercise price of the granted options is determined using the fair value of the Company’s share price at the
time of the options being granted.
Incentive Options issued prior to 31 March 2022 generally vest over three years and contain the requirement to
remain as an employee of the Company in order for the options to vest. Tranches of options are exercisable over
four to ten years from the relevant vesting date. No options can be exercised later than the tenth anniversary of the
final vesting date.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
16
Notes to the Consolidated Financial Statements
For the year ended 31 March 2024
Options issued after 1 April 2022 generally vest equally in three tranches over a four year period, with 1/3 on the
second, third and fourth anniversary of the issue. The Options are exercisable up to four years after vesting date.
Option holders are required to remain as an employee of the Company in order for options to vest. No options
can be exercised later than the fourth anniversary of the final vesting date. The exercise price increases annually for
each vested tranche at the equity cost of capital.
ACCOUNTING POLICY
All options are accounted for as equity settled share based payments as the Group has no legal or constructive
obligation to repurchase or settle in cash. The fair value of all options granted is recognised as an expense in the
Consolidated Statement of Comprehensive Income over their vesting period, with a corresponding increase in
the employee share option reserve. The options expense for the year ended 31 March 2024 was $1,189,000 (2023:
$1,273,000).
The fair value is determined at the grant date of the options and expensed on a straight-line basis over the vesting
period, based on the Group’s estimate of equity instruments that will eventually vest, with a corresponding increase
in equity. At the end of each reporting period, the Group revisits its estimate of the number of equity instruments
expected to vest. The impact of the revision of the original estimates, if any, is recognised in the Consolidated
Statement of Comprehensive Income such that the cumulative expense reflects the revised estimate, with a
corresponding adjustment to the share based payments reserve.
During the financial year ended 31 March 2024, there were no share options exercised (2023: Nil). There was no
resulting in increase in share capital (2023: Nil).
Movements in the number of options outstanding and their related weighted average exercise prices are as follows:
GROUP
20242023
Weighted average
exercise price
$
Options
#
Weighted average
exercise price
$
Options
#
Outstanding at 1 April 0.59 17,765,038 0.60 13,861,319
Granted0.30 14,711,546 0.60 4,293,215
Forfeited 0.59 (584,410) 1.04 (389,496)
Outstanding at 31 March0.45 31,892,174 0.59 17,765,038
Exercisable at 31 March0.4412,635,479 0.40 10,792,501

The Group used the Black-Scholes valuation model to determine the fair value of the equity instruments granted.
The Black-Scholes valuation model has been determined as the most appropriate method as it estimates the
theoretical value of options taking into account the impact of time and other risk factors. The significant inputs into
the Black-Scholes valuation model were the market share price at grant date, the exercise price shown below, the
expected annualised volatility of 50-106%, a dividend yield of 0%, an expected option life of between one and ten
years and an annual risk-free interest rate of between 0.65% and 5.63%.
The volatility measured is the standard deviation of continuously compounded share returns and is based on a
statistical analysis of daily share prices in the past one to ten years.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
17
Notes to the Consolidated Financial Statements
For the year ended 31 March 2024
Share options outstanding at the end of the reporting periods have the following expiry dates, vesting dates,
exercise prices and movements for the year ended 31 March 2024:
IssuedExpiryLow Exercise Price ($)High Exercise Price ($)Weighted Average Exercise Price ($)Opening Options as at 1 April 2023IssuedForfeitedExercisedExpiredClosing Options 31 March 2024Exercisable as at 31 March 2024
Apr 2014 -
Mar 2015
Sept 2024 -
Jan 2028
0.69 0.72 0.71 528,441 - - - - 528,441 528,441
Apr 2015 -
Mar 2016
Sept 2025 -
Mar 2029
0.50 0.60 0.51332,399 - - - - 332,399 332,399
Apr 2016 -
Mar 2017
Nov 2026 -
Jan 2030
0.48 0.60 0.57 327,607 - - - - 327,607 327,607
Apr 2017 -
Mar 2018
May 2028 -
Feb 2031
0.28 0.51 0.50 2,770,899 - - - - 2,770,899 2,770,899
Apr 2018 -
Mar 2019
Jun 2029 -
Nov 2031
0.23 0.28 0.24 69,098 - - - - 69,098 69,098
Apr 2019 -
Mar 2020
Aug 2030 -
Aug 2032
0.23 0.23 0.23 4,037,267 - - - - 4,037,267 4,037,264
Apr 2020 -
Mar 2021
Jun 2031 -
Jun 2033
0.22 0.80 0.31 2,142,108 - - - - 2,142,108 2,142,108
Apr 2021 -
Mar 2022
Aug 2032 -
Aug 2034
1.23 1.23 1.23 353,615 - (11,211) - - 342,404 260,737
Apr 2021 -
Mar 2022
Feb 2027 -
Feb 2031
1.15 1.25 1.23 3,000,000 - - - - 3,000,000 1,200,000
Apr 2022 -
Mar 2023
Dec 2026 -
Dec 2030
0.48 0.70 0.60 4,203,604 - (480,999) - - 3,722,605 966,926
Apr 2023 -
Mar 2024
Apr 2029 -
Oct 2031
0.25 0.64 0.30 - 14,711,546(92,200) - - 14,619,346 -
TOTALS0.45 17,765,038 14,711,546 (584,410) - - 31,892,174 12,635,479

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
18
Notes to the Consolidated Financial Statements
For the year ended 31 March 2024
9. CASH, CASH EQUIVALENTS AND SHORT TERM DEPOSITS
ACCOUNTING POLICY
Cash and cash equivalents includes cash in hand and deposits held on call with banks, and bank overdrafts. Term
deposits are also presented as cash equivalents if they have a maturity of three months or less from acquisition
date.
Short Term Deposits and Cash Equivalents include investments with ANZ, BNZ, Kiwibank, Westpac and Wells
Fargo (2023: ANZ, BNZ, Kiwibank, Westpac and Wells Fargo) with periods ranging up to 365 days. Funds held on
term deposit with ANZ, BNZ Westpac and Kiwibank can be accessed with one month’s notice at the request of the
authorised bank signatories of Pacific Edge Limited, but may incur fees and/or charges for early access.

GROUP
2024
($000)
2023
($000)
Cash and Cash Equivalents29,26133,229
Short Term Deposits21,00044,562
Total Cash, Cash Equivalents and Short Term Deposits50,26177,791
NZD42,81455,954
USD6,01020,399
AUD1,4361,429
EUR12
SGD-7
Total Cash, Cash Equivalents and Short Term Deposits50,26177,791
INTEREST INCOME
ACCOUNTING POLICY
Interest income is recognised using the effective interest method.
Interest on the bank balances ranges from 0% to 6.49% (2023: 0% to 5.99%) per annum.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
19
Notes to the Consolidated Financial Statements
For the year ended 31 March 2024
10. RECEIVABLES
ACCOUNTING POLICY
Receivables are initially measured at fair value and subsequently measured at amortised cost using the effective
interest rate method, less any provision for impairment. An allowance for impairment is made up of expected
credit losses based on the assessment of the trade receivables debt at the individual level for impairment, plus an
additional allowance on the remaining balance for potential credit losses not yet identified.
GROUP
2024
($000)
2023
($000)
Trade Receivables 2,551 2,780
Sundry Debtors 1,722 2,257
Accrued Interest 375 383
GST Refund Due 50 73
Total Receivables 4,698 5,493
There is no provision for impairment relating to the revenue from Cxbladder sales in New Zealand. All outstanding
sales are current and there are no expected credit losses on the amounts outstanding at balance date.
US Trade Receivables includes a provision for future refunds of $83,000 (2023: $271,000).
Sundry Debtors include accruals for grants and rebates that have not yet been paid. These are expected to be paid
once the relevant claims have been submitted. The Company has met all conditions of the claims and there is no
indication that there is impairment of these balances.
Included in trade receivables are the below amounts which were past due but not impaired. These relate to a
number of customers for whom there is no history of default.
GROUP
2024
($000)
2023
($000)
3 to 6 Months 75 436
Over 6 Months267 -
Total Overdue Trade Receivables 342 436
The foreign currency split of Receivables is:
GROUP
2024
($000)
2023
($000)
NZD2,355 2,375
USD 2,334 2,685
AUD 9 433
Total Receivables 4,698 5,493

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
20
Notes to the Consolidated Financial Statements
For the year ended 31 March 2024
11. INVENTORY
ACCOUNTING POLICY
Inventories are stated at the lower of cost and net realisable value. Cost is determined using the weighted average
formula.
GROUP
2024
($000)
2023
($000)
Laboratory Supplies 1,688 1,287
Total Inventory 1,688 1,287
The major items of Inventory are laboratory reagents, chemicals and Cxbladder urine sampling systems.
Laboratory supplies used during the year of $2,769,000 (2023: $2,540,000) are included within the Consolidated
Statement of Comprehensive Income in Laboratory Operations and Research.
12. OTHER ASSETS
GROUP
2024
($000)
2023
($000)
Prepayments
979 1,156
Security Deposits
249 244
Total Other Assets
1,228 1,400
Prepayments are largely made up of insurance, industry conferences and subscriptions. Security deposits are paid
to secure properties for lease in the US and to secure credit cards in the US.
13. PROPERTY, PLANT AND EQUIPMENT
ACCOUNTING POLICY
Property, Plant and Equipment are those assets held by the Group for the purpose of carrying on its business
activities on an ongoing basis. All Property, Plant and Equipment is stated at cost less subsequent accumulated
depreciation and any accumulated impairment losses. The cost of purchased assets includes the original purchase
consideration given to acquire the assets, and the value of other directly attributable costs that have been
incurred in bringing the assets to the location and condition necessary for their intended service. This includes the
laboratory equipment for the establishment of the laboratories.
Gains and losses on disposals are determined by comparing the net proceeds with the carrying amount and are
recognised within the Consolidated Statement of Comprehensive Income when they occur.
Depreciation
Depreciation of plant and equipment is based on writing off the assets over their useful lives, using the straight line
(SL) and diminishing value (DV) basis.
Main rates used are:
Plant and Laboratory Equipment 5% to 40% DV
Computer Equipment 5% to 67% DV
Leasehold Improvements 6% to 10% SL
Furniture and Fittings 5% to 25% DV
The assets’ useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
21
Notes to the Consolidated Financial Statements
For the year ended 31 March 2024

Plant &
Laboratory
Equipment
($000)
Computer
Equipment
($000)
Leasehold
Improvements
($000)
Furniture
& Fittings
($000)
Total
($000)
Cost
Balance at 1 April 20221,9173843923263,019
Additions1,53525912671,873
Disposals (48) (64) (23) (123) (258)
Translation difference371815171
Balance at 31 March 20233,4415973962714,705
Balance at 1 April 20233,4415973962714,705
Additions73189111832
Disposals(213) (29) (1) (11)(254)
Translation difference71117-89
Balance at 31 March 20244,0306684032715,372
Accumulated Depreciation
Balance at 1 April 2022 1,189 174 98 154 1,615
Depreciation expense 332 136 33 26 527
Disposals (177) (69) 57 (58) (247)
Translation difference 23 8 9 2 42
Balance at 31 March 20231,3672491971241,937
Balance at 1 April 2023 1,367 249 197 124 1,937
Depreciation expense 498 155 35 28 716
Disposals (211) (19) - (9) (239)
Translation difference 23 5 5 - 33
Balance at 31 March 20241,6773902371432,447
Carrying Amounts
At 1 April 2022 728 210 294 172 1,404
At 31 March 2023 2,074 348 199 147 2,768
At 31 March 20242,353 278 166 128 2,925

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
22
Notes to the Consolidated Financial Statements
For the year ended 31 March 2024
14. INTANGIBLE ASSETS
ACCOUNTING POLICY
Intellectual Property
The costs of acquired Intellectual Property are recognised at cost. All Intellectual Property has a finite life.
The carrying value of Intellectual Property is reviewed for impairment, where indicators of impairment exist.
Amortisation is charged on a diminishing value basis over the estimated useful life of the intangible assets (1-20
years). The estimated useful life and amortisation method is reviewed at the end of each reporting period.
The following costs associated with Intellectual Property are expensed as incurred during the research phases of
a project and are only capitalised when incurred as part of the development phase of a process or product within
development assets: Internal Intellectual Property costs including the costs of patents and patent application.
Software Development Costs
Costs associated with the development of software are held at cost. Amortisation is charged on a diminishing value
basis over the estimated useful life of the intangible assets (2-10 years). The estimated useful life and amortisation
method is reviewed at the end of each reporting period.
Cxbladder Development Costs
Costs associated with the development of Cxbladder products have been removed as an Intangible Asset
during the previous financial year with the $13,000 remaining value expensed in the Consolidated Statement of
Comprehensive Income for the year ended 31 March 2023.

Software
Development
Costs
($000)
Patents
($000)
Cxbladder
Development
Costs
($000)
Total
($000)
Cost
Balance at 1 April 20221,199550331,782
Additions97773 - 1,050
Disposals(12) - (33)(45)
Foreign Translation Difference4 - - 4
Balance at 31 March 20232,168623 - 2,791
Balance at 1 April 20232,168623 - 2,791
Additions5337 - 540
Foreign Translation Difference3 - - 3
Balance at 31 March 20242,704630 - 3,334
Accumulated Amortisation
Balance at 1 April 2022933395201,348
Amortisation expense35968 - 427
Disposals- - (20)(20)
Foreign Translation difference5 - - 5
Balance at 31 March 20231,297463 - 1,760
Balance at 1 April 20231,297463 - 1,760
Amortisation expense56754 - 621
Foreign Translation difference3 - - 3
Balance at 31 March 20241,867517 - 2,384
Carrying Amounts
At 1 April 202226615513434
At 31 March 2023871160 - 1,031
At 31 March 2024837113 - 950

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
23
Notes to the Consolidated Financial Statements
For the year ended 31 March 2024
15. SEGMENT INFORMATION
Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating
decision-maker. The chief operating decision-maker, who is responsible for allocating resources and assessing
performance of the operating segments, has been identified as the Chief Executive Officer who makes strategic
decisions.
There are two operating segments at balance date:
1. Commercial: The sales, marketing, laboratory and support operations to run the commercial businesses worldwide.
2. Research: The research and development of diagnostic and prognostic products for human cancer.
The reportable operating segment Commercial derives its revenue primarily from sales of Cxbladder tests and
the reportable operating segment Research derives its revenue primarily from grant income. The Chief Executive
Officer assesses the performance of the operating segments based on their net loss for the period.
Segment income, expenses and profitability are presented on a gross basis excluding inter-segment eliminations
to best represent the performance of each segment operating as independent business units. The segment
information provided to the Chief Executive Officer for the reportable segment described above, for the year
ended 31 March 2024, is shown below.
2024
Commercial
($000)
Research
($000)
Less:
Eliminations
($000)
Total External
Income
($000)
Income
Operating Revenue – External23,871 - 36 23,907
Other Income4894,400(3,567)1,322
Interest Income213,412 - 3,433
Foreign Exchange Gain 1 666 (36)631
Total Income24,3828,478(3,567)29,293
Expenses
Expenses40,00819,781(3,567)56,222
Depreciation & Amortisation 1,629 977 - 2,606
Total Operating Expenses41,63720,758(3,567)58,828
Loss Before Tax(17,255)(12,280) - (29,535)
Income Tax Expense - - - -
Loss After Tax(17,255)(12,280) - (29,535)
Net Cash Flow to Operating Activities(14,447)(11,303)- (25,750)

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
24
Notes to the Consolidated Financial Statements
For the year ended 31 March 2024
2023
Commercial
($000)
Research
($000)
Less:
Eliminations
($000)
Total External
Income
($000)
Income
Operating Revenue – External 19,616 - - 19,616
Other Income 467 2,245 (1,295) 1,417
Interest Income 18 2,743 - 2,761
Foreign Exchange Gain 5 2,325 - 2,330
Total Income 20,106 7,313 (1,295) 26,124
Expenses
Expenses 35,891 16,360 (1,295) 50,956
Depreciation and Amortisation 1,311 822 - 2,133
Total Operating Expenses 37,202 17,182 (1,295) 53,089
Loss Before Tax (17,096) (9,869) - (26,965)
Income Tax Expense - - - -
Loss After Tax (17,096) (9,869) - (26,965)
Net Cash Flow to Operating Activities (15,908) (9,667) - (25,575)
Eliminations
These are the intercompany transactions between the subsidiaries and the Parent. These are eliminated on
consolidation of Group results. The Research segment of the business utilise consumables and other components
that are purchased by the Commercial segments of the business, with the costs of these components allocated to
Research segment, and the Commercial segment recognising revenue from the sale.
Segment Assets and Liabilities Information
2024
Commercial
($000)
Research
($000)
Total
($000)
Total Assets11,443 54,005 65,448
Total Liabilities6,8713,95510,826

2023
Commercial
($000)
Research
($000)
Total
($000)
Total Assets 9,375 81,538 90,913
Total Liabilities 5,853 2,297 8,150
Additions to Non Current Assets for the period include:
Commercial
($000)
Research
($000)
Total
($000)
Property, Plant and Equipment790 42 832
Right of Use Assets 3,608 2153,823
Intangible Assets 533 7 540
Total Additions to Non Current Assets4,931 264 5,195
The amounts provided to the Chief Executive Officer with respect to total assets and total liabilities are measured
in a manner consistent with that of the financial statements. These assets and liabilities are allocated based on the
operation of the segment and the physical location of the asset.
There are no unallocated assets or liabilities.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
25
Geographic Split of Revenue and Non-Current Assets
The Group generates most of the operating revenue from Commercial tests from the US and New Zealand, and
also receives Grant revenue from Australia and New Zealand. Rest of World consists of Revenue from Australia and
Southeast Asia.
2024
($000)
2023
($000)
Operating and Grant Revenue
US 22,502 18,750
New Zealand 2,641 1,611
Rest of World 86 672
Total Operating and Grant Revenue 25,229 21,033
2024
($000)
2023
($000)
Non-Current Assets
US 4,343 1,907
New Zealand 3,229 3,035
Rest of World 1 -
Total Non-Current Assets 7,573 4,942
16. INCOME TAX
ACCOUNTING POLICY
The tax expense for the period comprises current and deferred tax. Tax is recognised in the Consolidated
Statement of Comprehensive Income, except to the extent that it relates to items recognised in other
comprehensive income or directly in equity. In this case, the tax is also recognised in other comprehensive income
or directly in equity, respectively.
The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the
balance sheet date in the countries where the Company and its subsidiaries operate and generate taxable income.
Management periodically evaluates positions taken in tax returns with respect to situations in which applicable
tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts
expected to be paid to the tax authorities.
Deferred income tax is provided in full, using the liability method, on temporary differences arising between the
tax bases of assets and liabilities and their carrying amounts in the financial statements in accordance with NZ
IAS 12. Deferred income tax assets are recognised to the extent that it is probable that future taxable profit will be
available against which the temporary differences can be utilised.
Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by
the balance sheet date and are expected to apply when the related deferred income tax asset is realised or the
deferred income tax liability is settled.
The Company and Group has incurred an operating loss for the 2024 financial year and no income tax is payable.
Notes to the Consolidated Financial Statements
For the year ended 31 March 2024

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
26
GROUP
2024
($000)
2023
($000)
Income tax recognised in the Consolidated Statement of
Comprehensive Income

Current tax expense - -
Deferred Tax in respect of the Current Year(3,217)(3,748)
Adjustments to deferred tax in respect to Prior Years284137
Deferred Tax Assets not recognised2,9333,611
Income tax expense--

The prima facie income tax on Pre-Tax Accounting Profit
from operations reconciles to:
Accounting loss before income tax(29,535)(26,965)
At the statutory Income Tax rate of 28%(8,270)(7,550)
Non-deductible Expenses5,9595,007
Difference in US, Singapore and Australian Income Tax Rates 8971,211
Prior Period Adjustment 284138
Tax Losses Utilised (1,803)(2,417)
Deferred Tax Assets not recognised 2,9333,611
Income tax expense reported in the Consolidated Statement
of Comprehensive Income
- -
Tax Losses
The group has losses to carry forward of approximately $144,471,000 (2023: $130,444,000) with a potential tax
benefit of $31,554,000 (2023: $28,913,000). The tax losses are split between the following jurisdictions:
Tax Losses
($000)
Tax Effect
($000)Rate
New Zealand13,1133,67128%
Australia3,30699230%
Singapore- - 17%
United States128,05226,89121%
Tax losses are available to be carried forward and offset against future taxable income subject to the various
conditions required by income tax legislation being complied with.
Deferred Research and Development Tax Expenditure:
The Group also has deferred research and development tax expenditure of $58,880,000 (2023: $51,462,000) to
carry forward and claim for income tax purposes in New Zealand in the future. This has a tax effect of $16,486,000
(2023: $14,409,000). The deferred research and development tax expenditure can either be carried forward and
offset against future income arising from the research and development, or subject to meeting the shareholder
continuity requirements can be offset against future other taxable income.
Deferred Tax Assets:
The Group does not recognise a deferred tax asset in the Consolidated Balance Sheet.
Imputation Credit Account
The Group has imputation credits of Nil (2023: Nil).
Notes to the Consolidated Financial Statements
For the year ended 31 March 2024

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
27
17. PAYABLES AND ACCRUALS
ACCOUNTING POLICY
Trade and Other Payables Due Within One Year
Trade payables are recognised at the value of the invoice received from a supplier. The carrying value of trade
payables is considered to approximate fair value as amounts are unsecured and are usually paid by the 30th of the
month following recognition.
GROUP
2024
($000)
2023
($000)
Trade Creditors2,153 2,178
Accrued Expenses 711 1,087
Employee Entitlements (refer below) 3,889 3,663
Total Payables and Accruals6,753 6,928
Payables and accruals are non-interest bearing and are normally settled on 30 day terms, therefore their carrying
value approximates their fair value.
The foreign currency split for Payables and Accruals is:
GROUP
2024
($000)
2023
($000)
NZD2,122 2,067
AUD202 299
USD4,423 4,521
SGD6 41
6,753 6,928
Employee Entitlements
Employee entitlements are measured at values based on accrued entitlements at current rates of pay. These include
salaries and wages accrued up to balance date and annual leave earned to, but not yet taken at balance date.
GROUP
2024
($000)
2023
($000)
Payroll Taxes 264 291
Holiday Pay 606 565
Accrued Wages3,019 2,807
Total Employee Entitlements3,889 3,663
Notes to the Consolidated Financial Statements
For the year ended 31 March 2024

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
28
18. SHARE CAPITAL
ACCOUNTING POLICY
Ordinary shares are described as equity.
Issue expenses, including commission paid, relating to the issue of ordinary share capital, have been written off
against the issued share price received and recorded in the Consolidated Statement of Changes in Equity.
Equity-settled share-based payments to employees and others providing services are measured at the fair value
of the equity instruments at the grant date. Details regarding the determination of the fair value of equity-settled
share based transactions are set out in Note 8.
GROUP
2024
($000)
2023
($000)
Ordinary Shares Authorised 294,400 294,317
Total Share Capital 294,400 294,317
All fully paid shares in the Group are Authorised and have equal voting rights and equal rights to dividends. All
Ordinary Shares are fully paid and have no par value.
Share Capital Group
2024 Shares
(000)
2024
($000)
2023 Shares
(000)
2023
($000)
Opening Balance 810,365 294,317 810,087 294,139
Issue of Ordinary Shares
- Employee Remuneration
1
906 83
278 182
Less: Issue Expenses
- - - (4)
Movement 906 83 278 178
Closing Balance 811,271 294,400 810,365 294,317

1) During the period 906,126 shares were issued as part of employees remuneration in lieu of cash payments at an average price
of $0.091 per share. (2023: 277,985 at $0.65).
There are 811,271,344 (March 2023: 810,365,218) ordinary shares on issue.
19. FOREIGN CURRENCY
ACCOUNTING POLICIES
Foreign Currency Transactions
The individual financial statements of the Group are presented in the currency of the primary economic
environment in which the entity operates (its functional currency). For the purpose of the Group financial
statements, the results and financial position of the Group entity are expressed in New Zealand dollars (‘NZ$’),
which is the functional currency of the Parent and the presentation currency for the Group financial statements.
In preparing the financial statements of the individual entities, transactions in currencies other than the entity’s
functional currency (foreign currencies) are recorded at the rates of exchange prevailing at the dates of the
transactions. At the end of each reporting period, monetary items denominated in foreign currencies are
retranslated at the rates prevailing at the end of the reporting period. Non monetary items denominated in foreign
currencies are translated at the rates prevailing on the date the transaction occurs.
Notes to the Consolidated Financial Statements
For the year ended 31 March 2024

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
29
Notes to the Consolidated Financial Statements
For the year ended 31 March 2024
Exchange differences are recognised in the Consolidated Statement of Comprehensive Income in the period in which
they arise.
Foreign Operations
For the purpose of presenting the Group financial statements, the assets and liabilities of the Group’s foreign
operations are expressed in New Zealand dollars using exchange rates prevailing at the end of the reporting period.
Income and expense items are translated at the average exchange rates for the period, unless exchange rates
fluctuated significantly during that period, in which case the exchange rates at the dates of the transactions are
used. Exchange differences arising, if any, are recognised in other comprehensive income and accumulated as a
separate component of equity in the Group’s foreign currency translation reserve. Such exchange differences are
reclassified from equity to profit or loss (as a reclassification adjustment) in the period in which the foreign operation
is disposed of.
Foreign Currency Translation Reserve
Exchange differences relating to the translation from the functional currencies of the Group’s foreign subsidiaries into
New Zealand dollars are brought to account by entries made directly to the Foreign Currency Translation Reserve.
20. RECONCILIATION OF CASH FLOWS TO OPERATING ACTIVITIES WITH OPERATING NET LOSS
GROUP
2024
($000)
2023
$000
Net Loss for the Period(29,535) (26,965)
Add Non Cash Items:
Depreciation 716 527
Loss on disposal of Property, Plant and Equipment 14 24
Amortisation 621 427
Employee Share options 1,189 1,273
Employee bonuses paid in shares in lieu of cash 83 182
Depreciation on right of use assets 1,267 1,179
Interest on finance leases shown in lease repayments 138 83
Total Non Cash Items 4,028 3,695
Add Movements in Other Working Capital items:
Decrease (Increase) in Receivables and Other Assets 964 (1,641)
(Increase) in Inventory (401) (280)
(Decrease) Increase in Payables and Accruals (174) 1,946
Effect of exchange rates on net cash(632) (2,330)
Total Movement in Other Working Capital(243) (2,305)
Net Cash Flows to Operating Activities(25,750) (25,575)

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
30
Notes to the Consolidated Financial Statements
For the year ended 31 March 2024
21. FINANCIAL INSTRUMENTS
ACCOUNTING POLICY
Foreign Currency Transactions
Financial instruments include cash and cash equivalents, short term deposits, receivables, security deposits, finance
lease liabilities and trade creditors. The particular recognition methods adopted are disclosed in the individual
policy statements associated with each item.
Managing Financial Risk
The Group’s activities expose it to the financial risks of changes in interest rate risk, credit risk, liquidity risk and
foreign currency risk. Management is of the opinion that the Company and the Group’s exposure to market risk
during the period and at balance date is defined as:
Risk FactorDescription
(i) Currency RiskFinancial assets and financial liabilities are denominated in NZD, USD, AUD, SGD and
EUR currencies
(ii) Interest Rate Risk Exposure to changes in Bank interest rates resulting in cash flow interest rate risk
(iii) Credit RiskRisk of financial loss if counterparty fails to meet contractual obligations
(iv) Liquidity RiskRisk the Group may not be able to meet its commitments as they fall due
(v) Other Price RiskNot applicable as no securities are bought, sold or traded
(i) Foreign Currency Risk
The Group faces the risk of movements in foreign currency exchange rates in relation to the New Zealand dollar.
The Group has significant operations in United States Dollars and less significant operations in Australian dollars,
Euros and Singapore dollars. As a result of this, the financial performance and financial position are impacted by
movements in exchange rates.
The Group manages foreign currency risk by purchasing overseas goods only when necessary and in line with the
approved treasury policy. It will also purchase foreign currency to fund overseas operations based on cash flow
forecasts in line with the approved treasury policy. There are no formal foreign currency hedges entered into.
A 10% increase or decrease in the foreign currency against the NZD will reduce/increase the loss reported by
approximately $260,000 (2023: $337,000) and increase/reduce equity by the same amount.
(ii) Interest Rate Risk
The Group’s interest rate risk arises from its cash and equivalents, and short term deposits. Cash and equivalents
comprise cash on hand and deposits at call with banks. Short term deposits comprise of term deposits placed with
New Zealand banks on fixed rates for different periods of time.
Management regularly review its banking arrangements to ensure it achieves the best returns on its funds while
maintaining access to necessary liquidity levels to service the Group’s day-to-day activities. The mixture of bank
deposits at floating interest rates and short term deposits at different rates over various periods of time mitigate
the risk of interest rates being received at less than market rates. The Group does not enter into interest rate
hedges.
A 1% increase or decrease in bank deposit interest rates will reduce/increase the loss reported by approximately
$491,000 and increase/reduce equity by the same amount (2023: $764,000).
(iii) Credit Risk
Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrument fails to
meet its contractual obligations.
The Group incurs credit risk from:
a) cash and short term deposits;
b) receivables in the normal course of its business; and
c) other assets.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
31
Notes to the Consolidated Financial Statements
For the year ended 31 March 2024
The Group has no significant concentration of credit risk other than bank deposits, with the exposure as at
31 March 2024 expressed as a percentage of total assets: 21.8% at ANZ, 23.3% at BNZ, 7.1% at Westpac, 22.9% at
Kiwibank and 1.6% at Wells Fargo. The Group’s cash and short term deposits are placed with high credit quality
financial institutions including major banks who have at least a A+ credit rating and concentrations are managed
within the approved treasury policy.
Regular monitoring of receivables is undertaken to ensure that the credit exposure remains within the Group’s
normal terms of trade. These receivables balances mainly relate to Kaiser Permanente, New Zealand customers,
and the New Zealand and Australian Government. Refer to note 10 for further details on expected credit losses for
receivables.
The Group continues to invoice for every billable test completed in the US, and the billing and reimbursement
process continues to maximise the cash that is received by the Group. The Group has included an accrual for tests
performed from 1 April 2023 to 31 March 2024 for which payment has not been received by 31 March 2024.
Regular monitoring of other assets is undertaken to ensure that the credit exposure is limited.
The carrying values of financial assets represent the maximum exposure to credit risk as represented below:
GROUP
Notes
2024
($000)
2023
($000)
Cash and Cash Equivalents929,26133,229
Short Term Deposits921,00044,562
Trade and Other Receivables (excludes GST)104,6485,420
Other Assets (excludes prepayments)12 249 244
55,15883,455
(iv) Liquidity Risk
Liquidity risk is the risk that the Group may encounter difficulty in raising funds at short notice to meet its
commitments as they fall due. Management maintains sufficient cash balances and uses cash flow forecasts to
determine future cash flow requirements. Liquidity risk is managed within the approved treaury policy. The Group
has one external loan for $300,000 which relates to to the New Zealand Research and Development Tax Incentive
in-year payment loan scheme. The Group also has three finance leases.
Payables and Accruals totaling $6,753,000 are due within 3 months of balance date (2023: $6,928,000).
Fair Values
In the opinion of the Directors, the carrying amount of financial assets and financial liabilities approximate their fair
values at balance date.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
32
Notes to the Consolidated Financial Statements
For the year ended 31 March 2024
22. RELATED PARTIES
A shareholder, the University of Otago, provided services, including rental space, car parking and use of University
Equipment, to the Group to the value of $493,000 (2023: $407,000). The Group has commitments totaling
$368,000 (2023: $344,000) with the University of Otago in the next financial year.
Key Management Compensation
Key management personnel comprise of Directors and the Chief Executive Officer of Pacific Edge Limited, and the
President of Pacific Edge Diagnostics USA Limited.
Refer to Note 8 for details of the Incentive Plan that includes key management remuneration.
GROUP
2024
($000)
2023
($000)
Salaries and Other Short Term Employee Benefits2,1472,483
Share Options Benefits646907
Total Employee Entitlements2,7933,390
Directors’ Fees
The current total Directors’ fee pool for non-executive Directors of Pacific Edge Limited, approved by the
shareholders at the Annual Shareholders Meeting on the 29th July 2021 was $465,000 per annum and was based
on six Directors. With the addition of Tony Barclay on 21 March 2022, the number of Directors increased to seven.
In accordance with NZX Listing Rule 2.11.3 which permits an issuer to increase the aggregate amount payable to
the Directors to take into account an additional Director without shareholder approval, the pool for non-executive
Directors of Pacific Edge increased to $529,000. The total amount of fees paid to Directors for the year ended
31 March 2024 was $500,000 (2023: $495,000).
The table below sets out the total fees approved for non-executive Directors of Pacific Edge Limited for the year
ended 31 March 2024 based on the positions held:
Position
Quantity
2024
Fee per
Director
2024
($)
Total
Directors
Fees Paid
2024
($)
Quantity
2023
Fee per
Director
2023
($)
Total
Directors
Fees Paid
2023
($)
Chair1$115,000$115,0001$115,000$115,000
Deputy Chair 1$70,000$70,0001$70,000$70,000
Non-executive Directors5$60,000$300,0005$60,000$300,000
Chair Audit & Risk Committee1$10,000$10,0001$10,000$10,000
Special Governance Allocation--$5,000---
Total Fee Pool$500,000$495,000

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
33
Notes to the Consolidated Financial Statements
For the year ended 31 March 2024
23. FINANCE AND OPERATING LEASE COMMITMENTS
ACCOUNTING POLICY
The Group leases various properties and equipment. Rental contracts vary depending on the type of asset
being leased. Lease terms are negotiated on an individual basis and contain a wide range of different terms and
conditions. The lease agreements do not impose any covenants, but leased assets may not be used as security for
borrowing purposes.
Contracts may contain both lease and non-lease components. The Group allocates the consideration in the
contract to the lease and non-lease components based on their relative stand-alone prices.
Leases are recognised as a right-of-use asset and a corresponding liability at the date at which the leased asset is
available for use by the Group. Each lease payment is allocated between the liability and finance cost. The finance
cost is charged to the Consolidated Statement of Comprehensive Income over the lease period to produce a
constant periodic rate of interest on the remaining balance of the liability for each period. The right-of-use asset is
depreciated over the shorter of the asset’s useful life and the lease term on a straight-line basis.
(i) Measurement basis
Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the
net present value of the following lease payments:
• fixed payments (including in-substance fixed payments), less any lease incentives receivable;
• variable lease payments that are based on an index or a rate;
• amounts expected to be payable by the lessee under residual value guarantees;
• the exercise price of a purchase option if the lessee is reasonably certain to exercise that option; and
• payments of penalties for terminating the lease, if the lease term reflects the lessee exercising that option.
Lease payments to be made under reasonably certain extension options are also included in the measurement of
the liability.
The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be readily
determined, which is generally the case for leases in the group, the lessee’s incremental borrowing rate is used. The
incremental borrowing rate is the rate that the individual lessee would have to pay to borrow the funds necessary
to obtain an asset of similar value to the right-of-use asset in a similar economic environment with similar terms,
security and conditions.
To determine the incremental borrowing rate, the Group:
• where possible, uses recent third-party financing received by the individual lessee as a starting point, adjusted to
reflect changes in financing conditions since third-party financing was received;
• uses a build-up approach that starts with a risk-free interest rate adjusted for credit risk for leases held by Pacific
Edge Limited, which does not have recent third-party financing; and
• makes adjustments specific to the lease, e.g. term, country, currency and security.
The Group is exposed to potential future increases in variable lease payments based on an index or rate, which are
not included in the lease liability until they take effect. When adjustments to lease payments based on an index or
rate take effect, the lease liability is reassessed and adjusted against the right-of-use asset.
Lease payments are allocated between principal and finance cost. The finance cost is charged to the Consolidated
Statement of Comprehensive Income over the lease period to produce a constant periodic rate of interest on the
remaining balance of the liability for each period.
Right-of-use assets are measured at cost comprising the following:
• the amount of the initial measurement of lease liability;
• any lease payments made at or before the commencement date;
• any initial direct costs; and
• restoration costs.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
34
Notes to the Consolidated Financial Statements
For the year ended 31 March 2024
Right-of-Use assets are generally depreciated over the shorter of the asset’s useful life and the lease term on
a straight-line basis. If the Group is reasonably certain to exercise a purchase option, the Right-of-Use asset is
depreciated over the underlying asset’s useful life.
Payments associated with short-term leases and leases of low-value assets are recognised on a straight-line basis
as an expense in profit or loss. Short-term leases are leases with a lease term of 12 months or less. Low-value assets
include IT equipment and small items of office furniture.
Right of Use Assets
GROUP
2024
($000)
2023
($000)
Cost
Opening Balance 4,191 3,605
Additions 3,823 337
Removals (Leases Completed)(134) -
Foreign Currency Translation117 249
Closing Balance 7,997 4,191

Accumulated Depreciation
Opening Balance 3,048 1,775
Depreciation 1,296 1,179
Reversal of Accumulated Depreciation (Leases Completed)(134) -
Foreign Currency Translation89 94
Closing Balance 4,299 3,048
Net Right of Use Assets Balance 3,698 1,143
Right of Use Assets Net Book Value
Buildings 3,638 1,128
Computer Equipment 60 15
3,698 1,143
Depreciation
Buildings 1,261 1,152
Computer Equipment 35 27
1,296 1,179
Expenses relating to Short Term and Low Value Leases 147 115
Total Cash Outflow relating to Leases 1,406 1,278

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
35
Notes to the Consolidated Financial Statements
For the year ended 31 March 2024
GROUP
Lease Liability
2024
($000)
2023
($000)
Opening Balance 1,222 1,923
Additions 3,823 337
Lease Repayments (1,406) (1,286)
Interest Charged 148 83
Foreign Currency Translation(14) 165
Closing Balance3,773 1,222
Split by:
Current Liability 1,264 811
Non-Current Liability2,509 411
3,773 1,222
The maturity of the Lease Liabilities is as follows:
Less than one year 1,264 811
One to two years 1,363 116
Two to three years 1,068 122
More than three years 78 173
3,773 1,222
24. OTHER COMMITMENTS AND CONTINGENT LIABILITIES
a) Contingent Liabilities
There were no known contingent liabilities at 31 March 2024 (March 2023: Nil). The Group has not granted any
securities in respect of liabilities payable by any other party whatsoever.
b) Capital Commitments
There are no capital commitments at 31 March 2024 (March 2023: Nil).

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
36
Notes to the Consolidated Financial Statements
For the year ended 31 March 2024
25. PROPOSED LOCAL COVERAGE DETERMINATION (LCD) AND LOCAL COVERAGE
ARTICLE (LCA) CHANGES - POTENTIAL IMPACT ON REVENUE
As described in Note 5, on 3 July 2020* Pacific Edge received notice of inclusion in the LCD resulting in the
Company receiving reimbursement for Cxbladder Monitor and Detect test from that date.
On 29 July 2022*, Pacific Edge became aware of proposed changes to the LCD/LCA whereby if the proposed
changes were issued as published then Cxbladder would no longer have coverage and the Company would not
qualify for reimbursement.
On 2 June 2023* Novitas, the Medicare Administrative Contractor (MAC) with jurisdiction for Pacific Edge’s
US laboratory issued a final Local Coverage Determination (LCD) L39365 that governs the reimbursement
of Cxbladder in the US by the US Centres for Medicare & Medicaid Services (CMS). The LCD determined that
Cxbladder would not qualify for coverage from Novitas for tests reimbursed by the CMS from 17 July 2023*. These
tests represent a significant portion of current Cxbladder testing revenue. Multiple companies that had existing
coverage or are seeking coverage, were similarly impacted by this proposal.
On the 6 July 2023* Pacific Edge received notification that LCD L39365 would not become final and Novitas would
propose it again as a draft LCD DL39365. The new draft would be subject to ‘notice and comment’ for 45 days
including an open public meeting and a written comment submission period.
On the 27 July 2023* Pacific Edge became aware that Novitas had republished the LCD (DL39365) without any
changes from LCD L39365, which if approved without further changes would mean Cxbladder (and multiple other
products from various companies) would not qualify for coverage from Novitas for tests reimbursed by the CMS.
Novitas provided for the statutory requirement for a 45-day notice and comment period commencing 27 July
2023* and finishing 9 September 2023*, during which time all interested stakeholders were able to submit
comments to Novitas. Pacific Edge, and a number of impacted parties submitted written submissions that argue
Cxbladder Triage, Detect and Monitor tests should retain Medicare coverage based on the clinical value they offer
to patients, clinicians, and healthcare payers.
Novitas may take up to 365 days from the original publication date (27 July 2023*) to withdraw or finalize the
LCD including a response to those comments. When finalized, Novitas must provide a minimum of 45 days’ notice
before the LCD becomes effective.
Pacific Edge received payment in line with the existing LCD/LCA (Local Coverage Article) for the twelve months
ended 31 March 2024, and to the date of approval of these Consolidated Financial Statements.
In the year to 31 March 2024, tests processed through our laboratory for Medicare and Medicare Advantage
patients represented approximately 60% of US commercial test volumes and generated approximately NZ $17.0m,
or 71% of Pacific Edge’s total operating revenue.
Whilst the LCD has yet to be finalised and the full impact on the Group is unable to be determined, management
and the Board have modelled a number scenarios relating to possible LCD outcomes. Under all modelled scenarios
there is sufficient liquidity in the form of cash and short term deposits to meet obligations and continue for the
foreseeable future, being at least 12 months from the date of approval of the financial statements. Accordingly, it is
the Board’s view that there are no material uncertainties related to events or conditions that may cast significant
doubt upon the entity’s ability to continue as a going concern for the purpose of these financial statements.
*All dates with an Asterix refer to US dates
26. SUBSEQUENT EVENTS
There are no subsequent events.

Independent auditor’s report
To the shareholders of Pacific Edge Limited
Our opinion
In our opinion, the accompanying consolidated financial statements of Pacific Edge Limited (the
Company), including its subsidiaries (the Group), present fairly, in all material respects, the financial
position of the Group as at 31 March 2024, its financial performance and its cash flows for the year
then ended in accordance with New Zealand Equivalents to International Financial Reporting
Standards (NZ IFRS) and International Financial Reporting Standards Accounting Standards (IFRS
Accounting Standards).
What we have audited
The Group's consolidated financial statements comprise:
●
the consolidated balance sheet as at 31 March 2024;
● the consolidated statement of comprehensive income for the year then ended;
● the consolidated statement of changes in equity for the year then ended;
● the consolidated statement of cash flows for the year then ended; and
● the notes to the consolidated financial statements, comprising material accounting policy
information and other explanatory information.
Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (New Zealand) (ISAs
(NZ)) and International Standards on Auditing (ISAs). Our responsibilities under those standards are
further described in the Auditor’s responsibilities for the audit of the consolidated financial statements
section of our report.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis
for our opinion.
Independence
We are independent of the Group in accordance with Professional and Ethical Standard 1 International
Code of Ethics for Assurance Practitioners (including International Independence Standards) (New
Zealand) (PES 1) issued by the New Zealand Auditing and Assurance Standards Board and the
International Code of Ethics for Professional Accountants (including International Independence
Standards) issued by the International Ethics Standards Board for Accountants (IESBA Code), and we
have fulfilled our other ethical responsibilities in accordance with these requirements.
Our firm carries out other services for the Group in the areas of half year review procedures and the
provision of training workshops. The provision of these other services and relationships have not
impaired our independence as auditor of the Group.
Key audit matters
Key audit matters are those matters that, in our professional judgement, were of most significance in
our audit of the consolidated financial statements of the current year. These matters were addressed
in the context of our audit of the consolidated financial statements as a whole, and in forming our
opinion thereon, and we do not provide a separate opinion on these matters.
PricewaterhouseCoopers, PwC Centre, 60 Cashel Street, PO Box 13-244, Christchurch 8141 New Zealand
T: +64 3 374 3000, www.pwc.co.nz
37

Description of the key audit matter How our audit addressed the key audit matter
Determining the timing of revenue recognition
for US revenue
As disclosed in Note 5 of the consolidated
financial statements, the timing of revenue
recognition for US based revenue varies by
revenue stream between completion of the
Cxbladder test and receipt of cash.
The Company has three material United States
(US) revenue streams:
1.
Coverage via Centers for Medicare and
Medicaid Services (CMS) and Medicare
Advantage;
2. Tests performed for Kaiser Permanente; and
3. Other private insurance.
In July 2020, the Company received Local
Coverage Determination ("LCD") and Local
Coverage Article (LCA) for CMS. This
determination created a set price for the
Company's tests of US$760 per test from July
2020, and established a clear transaction price for
the tests. This transaction price, along with a
history of payment, satisfies the NZ IFRS
requirement for revenue recognition. As disclosed
in note 25, on 27 July 2023 a draft LCD was
published which if approved without any changes
would mean that CxBladder tests would not
qualify for reimbursement. This has the potential
to significantly change the reimbursement of
Cxbladder tests in the US as the tests represent a
significant portion of current Cxbladder testing
revenue. The LCD/LCA is still in place and the
Company continues to receive reimbursement in
line with the existing LCD/LCA. The uncertainty in
respect of future operations is disclosed in Note
25.
In the US derived revenue for tests performed for
CMS, Medicare Advantage and Kaiser
Permanente have been recognised in advance of
cash being received. Revenue for these
customers is recognised once the test is invoiced.
All other US derived revenue is accounted for on
a cash receipt basis as disclosed in Note 5.
We determined this to be a key audit matter due
to the significance of the judgements applied by
Directors for revenue recognition and the potential
impact of changes in the proposed LCD/LCA.
Our audit procedures included the following:
We obtained an understanding of management's
processes and controls for the CMS, Medicare
Advantage, Kaiser Permanente and Private
Insurance US revenue streams, including the
relevant controls at the external billing
reimbursements service organisation.
We obtained the SOC1 System and Organisation
Controls Report for the external billing
reimbursement service organisation, and
evaluated the evidence provided over the design
and operating effectiveness of the relevant
controls.
We evaluated management's determination of the
timing of revenue recognition by:
●
Assessing the data supporting revenue
recognition for CMS, Medicare Advantage
and Kaiser Permanente to confirm that the
transaction price can be determined and
collectability is probable;
● Obtaining management's latest assessment,
correspondence and other information in
relation to the status of the proposed
LCD/LCA;
● Assessing the data supporting revenue
recognition for other private insurance to
confirm that the transaction price and
collectability is only probable when cash is
received;
● Performing subsequent receipt testing to
validate the probability of collection of the
year end receivables and performing look
back procedures over the prior year
receivables to test collection rates; and
● Evaluated whether revenue has been
recognised appropriately in accordance with
NZ IFRS 15.
PwC
38

Our audit approach
Overview
Overall group materiality: $769,000, which represents approximately
2.5% of (loss)/earnings before interest, tax, depreciation and
amortisation (EBITDA).
We chose (loss)/earnings before interest, tax, depreciation and
amortisation (EBITDA) as the benchmark because, in our view, it is
the benchmark against which the performance of the Group is most
commonly measured by users, and is a generally accepted
benchmark.
We tailored the scope of our audit in order to perform sufficient work
to enable us to provide an opinion on the consolidated financial
statements as a whole, taking into account the structure of the
Group, the accounting processes and controls, and the industry in
which the Group operates.
As reported above, we have one key audit matter, being:
●
Determining the timing of revenue recognition for US revenue
As part of designing our audit, we determined materiality and assessed the risks of material
misstatement in the consolidated financial statements. In particular, we considered where
management made subjective judgements; for example, in respect of significant accounting estimates
that involved making assumptions and considering future events that are inherently uncertain. As in all
of our audits, we also addressed the risk of management override of internal controls, including among
other matters, consideration of whether there was evidence of bias that represented a risk of material
misstatement due to fraud.
Materiality
The scope of our audit was influenced by our application of materiality. An audit is designed to obtain
reasonable assurance about whether the consolidated financial statements are free from material
misstatement. Misstatements may arise due to fraud or error. They are considered material if,
individually or in aggregate, they could reasonably be expected to influence the economic decisions of
users taken on the basis of the consolidated financial statements.
Based on our professional judgement, we determined certain quantitative thresholds for materiality,
including the overall Group materiality for the consolidated financial statements as a whole as set out
above. These, together with qualitative considerations, helped us to determine the scope of our audit,
the nature, timing and extent of our audit procedures and to evaluate the effect of misstatements, both
individually and in aggregate, on the consolidated financial statements as a whole.
How we tailored our group audit scope
We tailored the scope of our audit in order to perform sufficient work to enable us to provide an opinion
on the consolidated financial statements as a whole, taking into account the structure of the Group, the
accounting processes and controls, and the industry in which the Group operates.
PwC
39

Other information
The Directors are responsible for the other information. The other information comprises the
information included in the Annual Report, but does not include the consolidated financial statements
and our auditor's report thereon, and the climate statement to be published at a later date. The Annual
Report and climate statement are expected to be made available to us after the date of this auditor's
report.
Our opinion on the consolidated financial statements does not cover the other information and we will
not express any form of audit opinion or assurance conclusion thereon.
In connection with our audit of the consolidated financial statements, our responsibility is to read the
other information and, in doing so, consider whether the other information is materially inconsistent
with the consolidated financial statements or our knowledge obtained in the audit, or otherwise
appears to be materially misstated.
When we read the other information not yet received, if we conclude that there is a material
misstatement therein, we are required to communicate the matter to the Directors and use our
professional judgement to determine the appropriate action to take.
Responsibilities of the Directors for the consolidated financial statements
The Directors are responsible, on behalf of the Company, for the preparation and fair presentation of
the consolidated financial statements in accordance with NZ IFRS and IFRS Accounting Standards,
and for such internal control as the Directors determine is necessary to enable the preparation of
consolidated financial statements that are free from material misstatement, whether due to fraud or
error.
In preparing the consolidated financial statements, the Directors are responsible for assessing the
Group’s ability to continue as a going concern, disclosing, as applicable, matters related to going
concern and using the going concern basis of accounting unless the Directors either intend to liquidate
the Group or to cease operations, or have no realistic alternative but to do so.
Auditor’s responsibilities for the audit of the consolidated financial statements
Our objectives are to obtain reasonable assurance about whether the consolidated financial
statements, as a whole, are free from material misstatement, whether due to fraud or error, and to
issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance,
but is not a guarantee that an audit conducted in accordance with ISAs (NZ) and ISAs will always
detect a material misstatement when it exists. Misstatements can arise from fraud or error and are
considered material if, individually or in the aggregate, they could reasonably be expected to influence
the economic decisions of users taken on the basis of these consolidated financial statements.
A further description of our responsibilities for the audit of the consolidated financial statements is
located at the External Reporting Board’s website at:
https://www.xrb.govt.nz/assurance-standards/auditors-responsibilities/audit-report-1/
This description forms part of our auditor’s report.
PwC
40

Who we report to
This report is made solely to the Company’s shareholders, as a body. Our audit work has been
undertaken so that we might state those matters which we are required to state to them in an auditor’s
report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume
responsibility to anyone other than the Company and the Company’s shareholders, as a body, for our
audit work, for this report or for the opinions we have formed.
The engagement partner on the audit resulting in this independent auditor’s report is Maxwell John
Dixon.
For and on behalf of:
Chartered Accountants Christchurch
20 May 2024
PwC
41

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2024
42
COMPANY DIRECTORY
As at 31 March 2024
Issued Capital
811,271,344 Ordinary Shares
Registered Office
Level 12, Otago House
Cnr Moray Place and Princes Street
Dunedin
Directors
C. Gallaher – Chairman
B. Williams – Deputy Chairman
A. Masfen
S. Park
A. Stove
M. Green
A. Barclay
Chief Executive Officer
Peter Meintjes
Chief Financial Officer
Grant Gibson
Nature of Business
Research, develop and commercialise new
diagnostic and prognostic tools for the early
detection and management of cancers.
Auditors
PricewaterhouseCoopers
Christchurch
Bankers
Bank of New Zealand
Dunedin
ANZ
Dunedin
Kiwibank
Dunedin
Westpac
Dunedin
Wells Fargo
San Francisco
Solicitors
Anderson Lloyd
Level 12, Otago House
Cnr Moray Place and Princes Street
Dunedin
Securities Registrar
Link Market Services Limited
138 Tancred Street
Ashburton
Company Number
1119032
Date of Incorporation
27 February 2001
PACIFIC EDGE COMMUNICATIONS
Websites
www.pacificedgedx.com
www.cxbladder.com
Facebook
www.facebook.com/PacificEdgeLtd
www.facebook.com/Cxbladder
Twitter
@PacificEdgeLtd
@Cxbladder
LinkedIn
www.linkedin.com/company/pacific-edge-ltd

87 St David Street, PO Box 56, Dunedin, New Zealand
P +64 3 479 5800 F +64 3 479 5801
www.pacificedge.co.nz

---

Template
Results announcement
(for Equity Security issuer/Equity and Debt Security issuer)
Updated as at June 2023

Please do not amend or delete individual rows. As this template relates to prescribed content, changes to content
should only be made where it is clearly indicated that this is permitted, otherwise, if an Issuer considers a particular
element does not apply, mark the row as N/A, Any other changes to this prescribed form must first be approved by
NZX as required under NZX Listing Rule 3.26.1.

Results for announcement to the market
Name of issuer Pacific Edge Limited
Reporting Period 12 months to 31 March 2024
Previous Reporting Period 12 months to 31 March 2023
Currency NZD
Amount (000s) Percentage change
Revenue from continuing
operations
$23,907 22% Increase
Total Revenue $29,293 12% Increase
Net profit/(loss) from
continuing operations
($29,535) 10% Larger Loss
Total net profit/(loss) ($29,535) 10% Larger Loss
Interim/Final Dividend
Amount per Quoted Equity
Security
The Company does not propose to pay dividends to
shareholders
Imputed amount per Quoted
Equity Security
Not Applicable
Record Date Not Applicable
Dividend Payment Date Not Applicable
Current period Prior comparable period
Net tangible assets per
Quoted Equity Security
$0.066 $0.101
A brief explanation of any of
the figures above necessary
to enable the figures to be
understood
The Results Announcement should be read in conjunction with
the audited consolidated financial statements for the year ended
31 March 2024, the results presentation and commentary, all of
which have been released with this Results Announcement.
Authority for this announcement
Name of person authorised
to make this announcement
Peter Meintjes
Contact person for this
announcement
Peter Meintjes
Contact phone number 0800 555 563 (NZ) / +64 3 577 6733 (Overseas)
Contact email address peter.meintjes@pelnz.com
Date of release through MAP 21/05/2024
Audited financial statements accompany this announcement.